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ABSTRACT 
Morphine has been and continues to be one of the most potent and widely used 
drugs for the treatment of pain. Clinical and animal models investigating sex differences 
in pain and analgesia demonstrate that morphine is a more potent analgesic in males 
than in females; indeed, we report the effective dose of morphine for female rats is twice 
that of male rats. In addition to binding to the neuronal mu opioid receptor, morphine 
binds to the innate immune receptor toll-like receptor 4 (TLR4) on microglia. Morphine 
action at TLR4 initiates a neuroinflammatory response and directly opposes morphine 
analgesia. Our recent studies demonstrate that administration of chronic morphine 
activates microglia within the ventrolateral periaqueductal gray (vlPAG), a critical brain 
region for the antinociceptive effects of morphine, while blockade of vlPAG microglia 
increases morphine analgesia and suppresses the development of tolerance in male 
rats. Despite increasing evidence of the involvement of microglia in altering morphine 
efficacy, no studies have examined sex differences in microglia within the PAG. The 
present experiments seek to characterize the distribution and activity of vlPAG microglia 
in males and females using behavioral, immunohistochemical and molecular 
techniques, while demonstrating the sufficiency and necessity of vlPAG microglia to 
produce sex differences in morphine analgesia using site-specific pharmacological 
manipulation of TLR4. We also investigate a novel pharmacokinetic mechanism 
underlying the sexually dimorphic effects of morphine administration on microglial 
activity. Here, we address a fundamental gap in our current understanding of sex 
differences in morphine analgesia and establish a mechanistic understanding of how 
the activation of vlPAG microglia sex-specifically influences morphine analgesia. 
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1 INTRODUCTION  
 Sex differences in pain and treatment 
Pain is a highly subjective and unpleasant experience arising from the central 
nervous system. The perception of pain evolved as a protective mechanism to avoid 
potentially fatal encounters, and to discourage or change harmful behavior. However, 
pain does not always occur as a result of an overt injury; in some cases, the cause of 
pain cannot be identified. In these instances, long-lasting pain may become a frustrating 
and debilitating disease in and of itself--and can be extremely difficult to manage, let 
alone treat.  
Chronic pain--generally defined as pain lasting longer than three to six months--is 
one of the most commonly reported health problems in the US (Elzahaf et al., 2012; 
Kennedy et al., 2014). The National Health Interview Survey, conducted by the National 
Institutes of Health, reports that 55.7% of American adults had some level of pain within 
the previous three months, while 11.2 % had experienced chronic pain, that is, pain 
every day for the three months prior to the survey (Nahin, 2015). With so many 
individuals suffering from pain, it is no surprise that the economic burden of pain is 
massive. The National Academy of Sciences estimates the total annual cost of pain 
treatment to ranges from $560 to $635 billion annually in direct and indirect costs 
(Medicine, 2011).  
Chronic pain is a social and economic burden that impacts a large number of 
Americans, however, women appear to be disproportionately affected. Indeed, women 
have a much higher incidence rate of chronic pain conditions such as fibromyalgia, 
migraine, temporomandibular disorder, and osteoarthritis (Unruh, 1996; Fillingim et al., 
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2009; Mogil, 2012; Ruau et al., 2012; Buse et al., 2013; Kennedy et al., 2014). It is 
unclear if the female predominance of chronic pain conditions is due to higher 
susceptibility, or a greater likelihood for women to report pain, though many studies 
have attempted to tease apart these factors. Although women do use health care 
services more often than men for both painful and non-painful conditions (Bertakis et al., 
2000; Prevention, 2014), a recent report demonstrates that among men and women 
with the same diagnosis, reported pain levels were significantly higher in women (Ruau 
et al., 2012).  
Despite many years of study, it remains unclear if sex differences truly exist in pain 
perception. Human subjects show variable responses to experimentally induced pain, 
and sex differences in pain sensitivity are not always observed (Fillingim et al., 2009). 
This may be attributed to variability in testing conditions (i.e. the modality of pain being 
tested, reporting methods [self-report vs. threshold latency], or stage of menstrual 
cycle). However, when sex differences are observed, these studies overwhelmingly 
demonstrate that women are more sensitive to pain, and are more negatively affected 
by pain, than men [see (Fillingim et al., 2009; Mogil, 2012) for review]. 
 
 Opioids for the management of pain 
Opium derived from poppy plants has been used for thousands of years to 
alleviate pain and a variety of other ailments. Beginning in the early 1800’s, with the 
extraction of morphine from opium, opioids have been—and continue to be—the most 
effective and widely used pain treatment in the world (Rosenblum et al., 2008; Trescot 
et al., 2008). Approximately 3-5% of the adult US population is currently prescribed long 
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term opioid therapy (Boudreau et al., 2009); however, opioids induce many negative 
peripheral effects that prevent them from being efficacious when used long term. For 
example, opioids can induce respiratory depression and gastric immotility (Pasternak 
and Pan, 2013). In addition, prolonged use of opioids reduces their analgesic efficacy 
over time, thus requiring steadily larger doses to maintain analgesia—a phenomenon 
known as tolerance (Trescot et al., 2006; Trescot et al., 2008). Analgesic tolerance is 
reported to significantly impair pain relief (Gulur et al., 2014), and subsequent dose 
escalation increases the risk of developing addiction (Trescot et al., 2006). Finally, both 
chronic and acute opioid administration may result in opioid induced hyperalgesia, a 
paradoxical effect of opioids resulting in enhanced sensitivity to pain (see (Angst and 
Clark, 2006) for review).  
Of pain sufferers, women are more likely to be prescribed opioids—at higher 
doses and for longer periods of time—than men (Campbell et al., 2010; Frenk et al., 
2015; Manubay et al., 2015). This may have potentially important implications for the 
development of tolerance and addiction to opioids. From 1999 to 2015, more than 
183,000 people in the U.S. died from overdoses related to prescription opioids (Rudd et 
al., 2016), and in 2014, nearly two million Americans abused, or were dependent on, 
prescription opioids (2015). Although men are more likely to die from drug overdose 
than women, between 1999 and 2010, overdose deaths due to opioid pain relievers 
increased by 265% in men but increased by 415% in women ((CDC), 2013). 
There is increasing evidence suggesting that neither chronic nor acute treatment 
with opioids is an effective strategy for pain relief in women. Women consistently 
experience a greater preponderance of the negative side effects associated with acute 
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opioid consumption, including nausea, dysphoria, headache, and vomiting than men 
(Myles et al., 1997; Cepeda et al., 2003; Fillingim et al., 2005; Comer et al., 2010). In 
addition, opioids may not offer the same degree of pain relief in women. Similar to sex 
differences in pain sensitivity, sex differences in clinical pain management are also 
varied and misunderstood [see (Fillingim et al., 2009) for review]. Although several 
studies report that there is no sex difference in the analgesic efficacy of opioids in 
humans (Sarton et al., 2000; Glasson et al., 2002; Fillingim et al., 2005; Bijur et al., 
2008), when sex differences in opioid pain relief are detected, they demonstrate 
decreased analgesic efficacy in women (Cepeda and Carr, 2003; Miller and Ernst, 
2004; Aubrun et al., 2005). 
In contrast to clinical studies, preclinical research on pain relief using a variety of 
acute and persistent pain assays in rodents have repeatedly and consistently 
demonstrated that morphine is more effective in males than in females, with females 
requiring approximately twice as much morphine to achieve comparable pain-relief 
(Kepler et al., 1989; Boyer et al., 1998; Craft et al., 1999; Cicero et al., 2002; 
Krzanowska et al., 2002; Holtman et al., 2003; Ji et al., 2006; Loyd and Murphy, 2006; 
Wang et al., 2006; Loyd et al., 2008a; Posillico et al., 2015). Furthermore, several 
studies indicate that females also have greater morphine-induced hyperalgesia than 
their male counterparts (Holtman and Wala, 2005; Juni et al., 2008). Sex differences in 
opioid analgesia are not limited to morphine, indeed, greater pain relief is observed in 
male rats for almost every opioid tested (Barrett et al., 2002; Terner et al., 2003; Stoffel 
et al., 2005; Peckham and Traynor, 2006; Bai et al., 2015). 
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Figure 1.1.1 Inclusion of Sex in Preclinical Studies of Pain. (Mogil, 2012) 
 
Together, these studies clearly illustrate the necessity of sex-specific research on 
pain and pain management; however, the overwhelming majority of preclinical studies 
of pain (approximately 79%; Figure 1.1.1) are conducted exclusively in males (Mogil, 
2012). The study of pain and effective pain management in both sexes is not only 
important to ease the economic burden caused by chronic pain, but it is paramount to 
improve the lives of the immense number of men and women that suffer from chronic 
pain daily. 
 
 Mechanisms of pain and analgesia in the central nervous system 
Painful stimuli originating from the periphery are transduced by nociceptive fibers of 
the spinothalamic tract that are able to detect thermal or mechanical pain. Activation of 
pain-sensing channels results in excitation of two main classes of nociceptive fibers: 
myelinated A-delta fibers and unmyelinated C-fibers; contributing to sharp momentary 
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pain and slow diffuse pain, respectively. The signal of pain is transmitted via nociceptive 
afferents from the periphery to lamina I and II of the dorsal horn of the spinal cord, then 
to laminae IV-VI. Here, the signal crosses the midline and ascends to the brainstem, 
thalamus, rostral ventral medulla (RVM), periaqueductal gray (PAG), and ultimately to 
the cortex where pain is perceived (Millan, 1999).  
While ascending pathways alert the brain to painful stimuli (nociception), descending 
pathways carefully control and reduce pain (antinociception). The ventrolateral midbrain 
periaqueductal gray (vlPAG), and its descending projections to the rostral ventral 
medulla (RVM), are essential to exert control over antinociception (Basbaum et al., 
1978; Behbehani and Fields, 1979; Fields and Heinricher, 1985). For example, electrical 
stimulation of the PAG is sufficient to induce robust analgesia, such that invasive 
surgery can be performed in the absence of anesthesia (Reynolds, 1969). This effect 
appears to be opioid-dependent, as intra-PAG injection of the mu opioid receptor (MOR) 
antagonist (-)-naloxone attenuates stimulation-induced analgesia (Akil et al., 1976).  
Morphine and other opioids bind to neuronal MORs to modulate pain. (Jensen and 
Yaksh, 1986; Bernal et al., 2007; Loyd et al., 2008a). Activation of neuronal G-protein 
coupled MOR decreases the conductance of voltage-gated calcium channels and opens 
potassium channels, reducing the membrane potential to ultimately inhibit cell firing and 
decrease the probability of presynaptic neurotransmitter release (Millan, 2002). This 
effect occurs at several key sites (Figure 1.2.1):  
1) In the spinal cord, MOR-induced inhibition of neurons reduces the release of pro-
nociceptive transmitters (e.g. Substance P) from peripheral sensory neurons to 
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secondary ascending spinal neurons to decrease pain transmission, ultimately 
producing antinociception, or analgesia (Millan, 2002).  
2) The PAG contains a high density of MOR-containing neurons (Gutstein et al., 
1998; Commons et al., 1999; Wang and Wessendorf, 2002), and MOR binding at 
inhibitory GABAergic interneurons within the PAG decreases firing to descending pain-
inhibiting neurons. This is thought to disinhibit the PAG-RVM circuit, producing a net 
activation of the PAG-RVM, and inhibition of pain transmission at the spinal cord (Al-
Hasani and Bruchas, 2011; Stein, 2013; Lau and Vaughan, 2014). The importance of 
the PAG to opioid action and descending antinociception is further demonstrated as 
microinjection of opiate agonists directly into the PAG induces robust analgesia in male 
rats (Sohn et al., 2000; Loyd et al., 2008a). In addition, site-specific lesions of MOR-
positive neurons within the PAG significantly reduce the analgesic action of systemic 
morphine in male rats (Loyd et al., 2008a).  
 
Figure 1.2.1 A Model of Descending Analgesia. 
This figure demonstrates two key sites of opioid action in the CNS. Adapted from (Al-Hasani and 
Bruchas, 2011). 
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The PAG and its projections to the RVM and spinal cord possess innate sex 
differences in their anatomy and physiology that influence pain management and the 
effectiveness of opioid drugs. Specifically, our previous studies have found that females 
have approximately twice as many output neurons in the PAG-RVM pathway as their 
male counterparts; however, PAG-RVM output neurons are preferentially activated in 
males during persistent pain or following morphine injection (Loyd and Murphy, 2006; 
Loyd et al., 2007). In addition, males appear to have greater levels of MOR expression 
and binding within the PAG, likely contributing to the increased analgesic efficacy of 
morphine in males (Loyd et al., 2008a). However, selective ablation of vlPAG MOR-
expressing neurons significantly attenuates the response to morphine exclusively in 
males, indicating that the density of PAG MOR expression is significantly correlated with 
the degree of opioid analgesia in male, but not female, rats (Loyd et al., 2008a). These 
studies indicate that although MOR tone in the PAG is sexually dimorphic, density of 
MOR alone cannot solely account for the decreased efficacy of morphine observed in 
females.  
 
 Morphine action: pharmacokinetics, pharmacodynamics, and sex 
differences 
Following administration ~10% of morphine is directly absorbed or excreted 
unchanged (Christrup, 1997). The remaining ~90% of morphine is metabolized to form 
two active metabolites: morphine-3-glucuronide (M3G) and morphine-6-glucuronide 
(M6G). Metabolism occurs primarily in the liver (Coffman et al., 1997), but also by 
peripheral macrophages (Tochigi et al., 2005) and brain microglia (Togna et al., 2013), 
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indicating both peripheral and central metabolism of morphine. Isozymes in the uridine 
5'-diphospho-glucuronosyltransferase (UGT) 1 and 2 subfamilies metabolize morphine 
by addition of a glucuronic acid to the morphine substrate via Phase II metabolism 
(Coughtrie et al., 1989; Christrup, 1997). Peripheral enzymes UGT 1A1, 1A3, 1A6, 1A8, 
1A9, 1A10, and 2B7 are all capable of M3G glucuronidation, but M6G can only be 
formed by UGT2B7 in humans (Stone et al., 2003). In rats, the UGT 1A1, 1A6, 1A7, and 
2B1 enzymes synthesize both M3G and M6G (Togna et al., 2013). Almost all UGT 
enzymes preferentially synthesize M3G over M6G (~45-55% and 15% of metabolized 
product, respectively; (De Gregori et al., 2012)). 
Primary morphine metabolites have unique—and opposing—pharmacodynamic 
properties. M6G binds to MOR with high affinity and is a potent analgesic (Abbott and 
Palmour, 1988; Wittwer and Kern, 2006). Indeed, a recent meta-analysis suggests a 
substantial contribution of M6G to total analgesia following morphine administration 
(approx. 85-96%; (Klimas and Mikus, 2014)). On the other hand, M3G does not bind to 
MOR or produce analgesia (Loser et al., 1996). Rather, M3G produces allodynia (pain 
in response to a normally non-noxious stimuli) and hyperalgesia (exaggerated pain in 
response to a normally mild painful stimulus) (Lewis et al., 2010; Due et al., 2012). 
Further, administration of M3G is correlated with nociception (Smith and Smith, 1995) 
and behavioral excitation (e.g. “wet dog shakes”, excessive grooming) (Yaksh et al., 
1986; Bartlett et al., 1994), and actively opposes the analgesic effects of morphine and 
M6G (Smith et al., 1990; Ekblom et al., 1993).  
There is evidence to suggest sex differences are also present in morphine 
pharmacokinetics. For example, sexual dimorphism of UGT1 and 2 enzymes has been 
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observed in humans (Gallagher et al., 2010) and rats (Iwano et al., 2012); however, this 
is not surprising, given that these enzymes metabolize—and are directly influenced 
by—steroid hormones (Strasser et al., 1997). Although clinical studies show both the 
presence (Murthy et al., 2002) and absence (Sarton et al., 2000) of sex differences in 
glucuronide concentrations in humans, animal studies of morphine metabolites 
consistently show that M3G serum concentrations are ~2 times higher and the plasma 
ratio of M3G to morphine is ~5.5 times higher in female than in male rats (South et al., 
2001; Baker and Ratka, 2002; South et al., 2009).  
 
 Immune modulation of pain  
Pain transmission is dynamic and variable, and carefully modulated at every step 
from the periphery to the CNS. Pain can be “turned down” by descending 
antinociceptive processes such as endogenous opioid release and MOR binding, but it 
can also be “turned up” by pro-nociceptive processes stemming from the immune 
system. Although neurons have been the primary focus of pain transmission, non-
neuronal glial cells of the CNS, primarily microglia and astrocytes, are in key positions 
to modulate neuronal signaling and influence nociception.  
Astrocytes surround neurons at the synapse, and actively participate in neuronal 
signaling (Haydon et al., 2009). Microglia layer themselves across the brain and survey 
the neuronal space for pathogens or chemicals associated with cellular distress, known 
as “alarmins” (Davalos et al., 2005; Bianchi, 2007). In the event of cellular distress (e.g. 
tissue injury or the presence of pathogens/bacteria), neurons release “alarmins” such as 
fractalkine (CX3CL1), nitric oxide, substance P, calcitonin gene related peptide, ATP, 
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glutamate and prostaglandins (Watkins et al., 2007; Watkins et al., 2009). These 
“alarmins” bind to pattern recognition receptors, known as “toll-like” receptors (TLRs), 
located primarily on microglia, and to a lesser extent, on astrocytes (Hutchinson et al., 
2008a; Watkins et al., 2009). Binding of pathogenic or damage-associated molecules to 
microglial toll-like receptor 4 (TLR4) results in the transition of microglia from a ‘resting’ 
to a ‘reactive’ (or ‘activated’) state (Watkins and Maier, 2003; Bianchi, 2007; Watkins et 
al., 2009; Buchanan et al., 2010).  
‘Activated’ microglia are primary contributors to pain modulation. Microglia release 
pro-nociceptive molecules such as cytokines (interleukins [IL]-1, -6, and -10; tumor 
necrosis factor [TNF]), chemokines, cyclooxygenase-2 (COX-2), prostaglandin E2 
(PGE2), and reactive oxygen species (Bonizzi and Karin, 2004; Doyle and O'Neill, 
2006). These glial products cause down-regulation of inhibitory GABAA receptors and 
up-regulation of excitatory AMPA and NMDA receptors on neurons, and decrease 
glutamate transporters to increase extracellular concentrations of glutamate, together 
producing a net increase in neural excitability (Ogoshi et al., 2005; Stellwagen et al., 
2005; Watkins et al., 2005; Yan et al., 2014; Eidson et al., 2016); also see (Tilleux and 
Hermans, 2007) for review. Glial release of pro-inflammatory molecules and subsequent 
neuronal excitability results in the sensitization of nociceptive neurons and enhanced 
pain (Watkins and Maier, 2003).  
Activation of CNS microglia, and subsequent release of pro-inflammatory mediators, 
is now well-established to play a role in pain. For example, ‘activated’ microglia are 
observed in essentially every known animal model of clinical pain, including nerve 
damage, bone cancer, migraine, and many others [see (Watkins et al., 2007) for 
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review]. Furthermore, activation of glial cells with inflammatory CFA (complete Freund’s 
adjuvant) or the TLR4 agonist lipopolysaccharide (LPS; a component of gram-negative 
bacteria), induces robust allodynia and hyperalgesia (Watkins et al., 1994; 
Raghavendra et al., 2004a; Sorge et al., 2011). On the other hand, blocking glial cell 
function or glial release of pro-inflammatory molecules prevents or reverses allodynia 
and hyperalgesia (Maier and Watkins, 1998; Plunkett et al., 2001; Raghavendra et al., 
2003; Ledeboer et al., 2005; Hutchinson et al., 2008a). These data demonstrate that 
glial cells, via TLR4, communicate bidirectionally with neurons, and their activation is 
associated with increased nociception. 
 
 Opioids bind to immune receptors on glia 
Microglia and astrocytes are relatively new targets in the search for improved 
pain therapeutics (Tanga et al., 2005; Milligan and Watkins, 2009; Nicotra et al., 2012). 
Morphine binds to the myeloid differentiation factor 2 (MD2) co-receptor of TLR4 
(Hutchinson et al., 2010). Thus, similar to pathogenic molecules, morphine can initiate a 
pro-inflammatory cascade, ultimately leading to cytokine release and neuronal 
excitation that paradoxically reduces its own analgesic efficacy (Stellwagen et al., 2005; 
Hutchinson et al., 2007; Hutchinson et al., 2010; Franchi et al., 2012; Li, 2012; Eidson 
and Murphy, 2013a; Thomas et al., 2015). Unlike the MOR which can only bind the 
negative isomer of opioids, TLR4 binds opioids in a non-stereoselective fashion, such 
that both negative (-) and positive (+) isomers bind to TLR4 to affect glial signaling 
(Hutchinson et al., 2010) (Figure 1.3.1). It is important to note that although MORs have 
13 
been localized on microglia (Chao et al., 1997), acute morphine does not activate 
microglia via MOR (Gessi et al., 2016). 
  
Figure 1.3.1. TLR4 Binds (-) and (+) Isomers of Opioid Ligands.  
TLR4 binds opioids in a nonstereoselective fashion. Adapted from (Hutchinson et al., 2010) and (Eidson 
et al., 2016). 
 
To date, many studies have shown a link between glial activation and decreased 
morphine efficacy. Activation of TLR4 by morphine has also been linked with many of 
the negative side effects associated with morphine use, such as morphine-induced 
hyperalgesia (Raghavendra et al., 2004b), withdrawal (Ledeboer et al., 2007), and 
tolerance (Song and Zhao, 2001; Raghavendra et al., 2002; Raghavendra et al., 2004b; 
Mika et al., 2009; Bai et al., 2014). Inhibition of microglia or TLR4 signaling, or blockade 
of proinflammatory cytokine production, result in a potentiation of morphine-induced 
analgesia (Raghavendra et al., 2004b; Watkins et al., 2005; Hutchinson et al., 2008b; 
Hutchinson et al., 2008a; Hutchinson et al., 2010; Li, 2012; Eidson and Murphy, 2013a; 
Bai et al., 2014).  
We have recently reported that the PAG is a critical neural target for morphine-
induced glial activation and pain modulation in male rats. Chronic systemic 
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administration of morphine activates TLR4 within the PAG to induce local cytokine 
release and oppose analgesia (Eidson and Murphy, 2013b; Eidson et al., 2016). 
Further, specific inhibition of TLR4 with (+)-naloxone directly into the PAG increases 
analgesia and blocks the development of tolerance to chronic morphine (Eidson and 
Murphy, 2013a; Eidson et al., 2016).  
Morphine binding at TLR4 is now well accepted, but notably, many other clinically 
prescribed opioids, such as oxycodone and fentanyl, also bind to TLR4 (Hutchinson et 
al., 2010). In addition, the active morphine metabolite M3G binds to TLR4 with high 
affinity (Hutchinson et al., 2010), causing robust activation of microglia accompanied by 
cytokine release and the development of hyperalgesia (Lewis et al., 2010; Due et al., 
2012). Together, this implies that many relevant opioids may have neuro-excitatory 
effects, and oppose analgesia via TLR4. Importantly, the analgesic metabolite of 
morphine, M6G, does not appear to bind to TLR4 (Hutchinson et al., 2010), and is not 
associated with pro-inflammatory glial activity (Carrigan and Lysle, 2001). Thus, M6G 
and potential drugs that do not activate immune cells may produce greater analgesia 
and represent a favorable alternative to the commonly used immune-activating opioids.  
 
 Sex differences in innate immunity 
Sex differences in immunity have been well demonstrated, with females having a 
more robust immune system at baseline, and more reactive immune response to 
perturbation than males [for review, see (Marriott and Huet-Hudson, 2006), (Garcia-
Segura and Melcangi, 2006), and (Schwarz and Bilbo, 2012)]. For example, in the 
peripheral immune system, female mice have higher baseline titers of immunoglobulins 
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(Klein, 2000), and splenocyte blastogenic responses to T and B cell mitogens than 
males (Schneider et al., 2006). Females also demonstrate increased resistance to 
bacterial and parasitic infection compared with males (Klein, 2004). Sex differences in 
the release of pro-inflammatory molecules (i.e. cytokines) following immune challenge 
has been well documented, however, the direction of the effect is not consistent--
showing increased glial activity in both males (Drew and Chavis, 2000; Aulock et al., 
2006) and females (Calippe et al., 2008; Calippe et al., 2010; Loram et al., 2012; Engler 
et al., 2016). In a recent clinical study, LPS immune challenge was shown to elicit a 
greater cytokine response in women that was accompanied by increased hyperalgesia 
to cold/heat pain suggesting that clinical reports of sex differences in pain sensitivity 
may be the result of a pro-nociceptive cytokine response that is potentiated in women 
(Karshikoff et al., 2015).  
Although increased immune responsivity in females is thought to be 
neuroprotective, over-activation of the immune system can be pathological (Streit et al., 
2004). Females demonstrate increased inflammation and hyperalgesia in response to 
immune challenge compared with males (Cook and Nickerson, 2005), which may make 
females more susceptible to long-term effects of inflammation than their male 
counterparts (LaPrairie and Murphy, 2007). Exaggerated inflammatory responses may 
also underlie the increased prevalence of auto-immune disorders (Whitacre, 2001; 
Cooper and Stroehla, 2003) and chronic inflammatory conditions observed in females.  
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 Dissertation aims 
Previous research has investigated various factors potentially driving sex differences 
in morphine analgesia, with few conclusive results to a single underlying mechanism. 
Previous work from our lab demonstrates that males have more MOR in the vlPAG 
(Loyd et al., 2008a) and respond more robustly to morphine agonism than females 
(Zubieta et al., 2002; Loyd and Murphy, 2006, 2009); however, female analgesia 
appears to have a limited relation with MOR density (Loyd et al., 2008a). This suggests 
that despite physiological differences in MOR, additional or parallel underlying 
mechanisms should be considered. 
Given robust sex differences in immune function, and known links between 
immune function and morphine efficacy, we suggest that immune modulation is a likely 
novel mechanism that may be decreasing analgesic efficacy of morphine in females. 
See summary Figure 1.4.1. Thus, we propose our overarching hypothesis that sex 
differences in the analgesic effects of morphine are due to sexually dimorphic 
responses of vlPAG microglia. Specifically, we hypothesize that females have 
increased activation of microglia compared with males, thus the analgesic efficacy of 
morphine is decreased to a greater degree in females. In addition, we hypothesize that 
sex differences in morphine pharmacokinetics exacerbate this effect via increased M3G 
binding to TLR4 (and subsequently increased glial reactivity) in females. We will test 
these hypotheses in two specific aims: 
 
Specific Aim 1: Characterize vlPAG microglia activity in males and females and 
establish the role of TLR in mediating the sexually dimorphic effects of morphine. 
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Despite evidence of sex-specific responses to immune challenge (Calippe et al., 2008; 
Calippe et al., 2010), and a well-established relationship between immune activation 
and pain (Watkins et al., 2007), TLR4-mediated glial activity has not been examined in 
any brain region involved in pain processing in females, and the contribution of TLR4 to 
morphine efficacy in females remains to be tested. Our previous studies demonstrate 
that TLR4 signaling within the PAG modulates morphine analgesia in male rats (Eidson 
and Murphy, 2013b), however, no studies have examined the role of PAG TLR4 in 
females. This aim will 1) examine sex differences in distribution and activation of vlPAG 
microglia using behavioral, anatomical, and molecular techniques at baseline or 
following immune activation by either the TLR4 agonist LPS, or morphine. Furthermore, 
2) we will demonstrate a mechanistic role of PAG microglia in modulating morphine 
efficacy in males and females using site-specific injections of a TLR4 agonist and 
antagonist to examine the sufficiency and necessity of vlPAG TLR4 to produce sex 
differences in morphine analgesia. 
 
Specific Aim 2: Investigate a pharmacokinetic mechanism involved in the 
sexually dimorphic activation of microglia. Morphine is converted into two active 
glucuronides: M3G and M6G. M6G binds to MOR and is a potent analgesic, while M3G 
binds to TLR4 with high affinity to activate glia, thus opposing the analgesic effects of 
morphine and M6G. In rats, M3G serum concentrations are ~2 times higher and the 
ratio of M3G to morphine is ~5.5 times higher in females than males (Baker and Ratka, 
2002). Despite known sex differences in morphine metabolism, a mechanistic 
investigation of morphine metabolites on microglial activation or morphine analgesia has 
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never been performed. Therefore, this aim will 1) examine behavioral responses to M3G 
and M6G using vlPAG site-specific injections; and 2) examine the contribution of 
morphine metabolites to the activation of microglia. 
These studies are the first to describe a role of microglia in producing sex 
differences in morphine analgesia. Furthermore, we suggest novel methods to 
improve current opioid-based pain management via inhibition of glial TLR4, and 
illustrate the necessity for sex-specific research and individualized treatment 
strategies for the management of pain. 
 
 
Figure 1.4.1. Summary Figure Describing a Potential Mechanism Underlying Reduced Morphine Efficacy 
in Females. 
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Abstract 
Although morphine remains the primary drug prescribed for alleviation of severe or 
persistent pain, both preclinical and clinical studies have shown that females require 2-3 
times more morphine than males to produce comparable levels of analgesia. In addition 
to binding to the neuronal μ opioid receptor (MOR), morphine binds to the innate 
immune receptor toll-like receptor 4 (TLR4) localized primarily on microglia. Morphine 
action at TLR4 initiates a neuroinflammatory response that directly opposes the 
analgesic effects of morphine. Here we test the hypothesis that the attenuated response 
to morphine observed in females is the result of increased microglia activation in the 
periaqueductal gray (PAG), a central locus mediating the antinociceptive effects of 
morphine. We report that while no overall sex differences in the density of microglia 
were noted within the PAG of male or female rats, microglia exhibited a more “activated” 
phenotype in females at baseline, with the degree of activation a significant predictor of 
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morphine ED50 values. Priming microglia with LPS induced greater microglia activation 
in the PAG of females compared with males that was accompanied by increased 
transcription levels of IL-1ß and a significant rightward shift in the morphine dose 
response curve. Blockade of morphine binding to PAG TLR4 with (+)-naloxone 
significantly potentiated morphine antinociception in females such that no sex 
differences in ED50 were observed. These results demonstrate that PAG microglia are 
sexually dimorphic in both basal and LPS-induced activation, and contribute to the 
sexually dimorphic effects of morphine in the rat. 
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 Introduction 
Opioid therapy remains a primary strategy for severe and chronic pain 
management with 3-4% of adults in the US receiving long-term opioid therapy (Dowell 
et al., 2016);  however, preclinical studies using a variety of acute and persistent pain 
assays have repeatedly demonstrated that morphine is more effective in males than in 
females (Dawson-Basoa and Gintzler, 1993; Mogil et al., 2000; Wang et al., 2006; Craft 
et al., 2008; Loyd et al., 2008a). Decreased analgesic efficacy is often countered with 
dose escalation, leading to increased risk of negative side effects associated with opiate 
consumption, including respiratory depression, tolerance, and overdose (Trescot et al., 
2006).  
Several exogenous opioids, including morphine, bind to the myeloid 
differentiation factor 2 (MD-2) co-receptor of the innate immune receptor toll-like 
receptor 4 (TLR4) (Hutchinson et al., 2010). TLR4 is located primarily on microglia 
(Lehnardt et al., 2002; Lehnardt et al., 2003; Jou et al., 2006; Marinelli et al., 2015) and 
activation of the MD2-TLR4 complex promotes the expression of pro- and anti-
inflammatory compounds including cytokines (tumor necrosis factor alpha [TNF], 
interleukins [IL-1β, IL-6, IL-10]), chemokines (CXCL3) and prostaglandin E2 (PGE2) 
(Bonizzi and Karin, 2004; Doyle and O'Neill, 2006; Hutchinson et al., 2008c; Hutchinson 
et al., 2010). Activation of TLR4 and the release of proinflammatory signaling molecules 
increases neuronal excitability via upregulation of α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptor  (Ogoshi et al., 2005; Stellwagen et al., 2005), 
downregulation of glutamate transporter (Yan et al., 2014; Eidson et al., 2016), and 
decreased  γ-Aminobutyric acid (GABAA) receptor expression, that together, induce 
22 
hyperalgesia. Therefore, morphine paradoxically reduces its analgesic efficacy through 
TLR4-mediated inflammation (Song and Zhao, 2001; Hutchinson et al., 2007; 
Hutchinson et al., 2010; Franchi et al., 2012; Li, 2012; Wang et al., 2012; Eidson and 
Murphy, 2013b, a; Eidson et al., 2016).  
The ventrolateral midbrain periaqueductal gray (vlPAG) is a critical neural locus 
mediating the antinociceptive effects of morphine (Morgan et al., 2005; Loyd et al., 
2007). Direct PAG administration of morphine induces long-lasting analgesia, while 
identical administration of the opioid antagonist (-)-naloxone or lesions of PAG μ opioid 
receptor (MOR) completely abolish the antinociceptive effects of systemic morphine 
(Loyd et al., 2008a). The antinociceptive effects of intra-PAG morphine are highly sex-
dependent, such that in males, the half-maximal antinociceptive dose (ED50) of 
morphine ranges from 1.2-1.6 µg/µl, while in females, ED50 values range from 16 to >50 
µg/µl (Krzanowska and Bodnar, 1999; Loyd et al., 2008a; Bobeck et al., 2009).  
MD-2 is densely expressed within the PAG, and administration of morphine 
activates PAG microglia, opposing the analgesic effects of morphine and inducing 
tolerance in a TLR4-dependent manner (Eidson and Murphy, 2013b, a; Eidson et al., 
2016). Similarly, blockade of PAG microglial activation in male rats via TLR4 inhibition 
potentiates morphine analgesia and suppresses the development of tolerance (Eidson 
and Murphy, 2013a; Eidson et al., 2016). Here, we test the hypothesis that the sexually 
dimorphic effects of morphine are due to sex differences in microglia activation in the 
PAG.  
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 Materials and methods 
 General methods 
Subjects. Age matched (60-90 day old) intact male and normally cycling female 
Sprague Dawley rats (Charles River) were used. Animals were pair-housed with the 
same sex on a 12:12 h light/dark cycle (lights on at 08:00). Access to food and water 
was available ad libitum throughout the experiments except during behavioral testing. 
All studies were approved by the Institutional Animal Care and Use Committee at 
Georgia State University, and performed in compliance with Ethical Issues of the 
International Association for the Study of Pain and National Institutes of Health. All 
efforts were made to reduce the number of animals used in these experiments and to 
minimize pain and suffering. 
Vaginal cytology. Vaginal lavages were performed daily beginning 7 days prior to 
testing to confirm that all female rats were cycling normally and to record cycle stage at 
the time of testing. Proestrus was identified as a predominance of nucleated epithelial 
cells and estrus was identified as a predominance of cornified epithelial cells. Diestrus 1 
was differentiated from Diestrus 2 by the presence of leukocytes. Rats that appeared 
between phases were noted as being in the more advanced stage (Loyd et al., 2007). 
 
 Experiment 1: Influence of acute morphine administration on PAG 
microglia expression and morphology  
To determine if morphine activation of microglia was sexually dimorphic, male 
and female rats received a single ED50 injection of (-)-morphine sulfate (5 mg/kg; 
National Institute on Drug Abuse (NIDA), Bethesda, MD) or saline (1 mg/kg) 
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subcutaneously (s.c.) and were sacrificed by transcardial perfusion 15, 30, or 60 
minutes post-injection. An additional group of animals served as handled controls, 
resulting in a total of 6-8 animals per sex per group, total number of animals 54 males, 
48 females. 
Immunohistochemistry. At the end of the experiment, animals were given a lethal 
dose of SomnaSol® (0.5-1.0 ml/kg; i.p.) and transcardially perfused with 200-250 ml of 
0.9% sodium chloride containing 2% sodium nitrite as a vasodilator followed by 300 ml 
of 4% paraformaldehyde in 0.1M potassium phosphate buffered saline (KPBS). Brains 
were post-fixed in 4% paraformaldehyde and KPBS for 48 hours and then placed in a 
30% sucrose solution and stored at 4°C. Brains were sectioned coronally at 25 µm with 
a Leica 2000R freezing microtome and stored free-floating in cryoprotectant-antifreeze 
solution at -20°C. A 1:6 series through the rostrocaudal axis of each brain was 
processed for ionized calcium binding adaptor molecule 1 (Iba-1) immunoreactivity 
using standard immunhistochemical techniques as previously described (Loyd and 
Murphy, 2006). Iba-1 was selected as it is specific to microglia and is constitutively 
expressed across all stages of activation, allowing for both qualitative and quantitative 
assessment in both healthy/uninjured animals as well as endotoxin- and morphine-
treated animals. Briefly, sections were rinsed extensively in KPBS to remove 
cryoprotectant and then incubated in a rabbit anti-Iba-1 (WAKO Chemicals, Richmond, 
VA; 1:10K) primary antibody solution in KPBS containing 1.0% Triton-X for one hour at 
room temperature followed by 72 hours at 4°C. After rinsing with KPBS, the tissue was 
incubated for one hour in biotinylated donkey anti-rabbit IgG (Jackson Immunoresearch; 
West Grove, PA, 1:600), then rinsed with KPBS and incubated for one hour in an avidin-
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biotin peroxidase complex (1:10; ABC Elite Kit, Vector Labs). After rinsing in KPBS and 
sodium acetate (0.175 M; pH 6.5), microglia immunoreactivity was visualized as a black 
or purple reaction product using nickel sulfate intensified 3,3′-diaminobenzidine (DAB) 
solution (2mg/10ml) containing 0.08% hydrogen peroxide in sodium acetate buffer. 
Following incubation in DAB, tissue was rinsed in sodium acetate buffer followed by 
KPBS. Sections were then mounted out of KPBS onto gelatin-subbed slides, air-dried 
and dehydrated in a series of graded alcohols. Tissue-mounted slides were then 
cleared in xylene and glass cover-slipped using Permount mounting medium. 
Densitometry and presentation.  Levels of Iba-1 immunoreactivity in the vlPAG 
were compared across sex and treatment groups using semiquantitative densitometry 
as previously described (Loyd et al., 2008a; Laprairie and Murphy, 2009; Eidson and 
Murphy, 2013a). Twelve-bit grayscale images were captured using QImaging Retiga 
EXi CCD camera attached to a Nikon microscope and iVision Image analysis software 
(BioVision Technologies). The region of interest included sections through six 
representative levels of the rostrocaudal axis of the vlPAG (Bregma -6.72, -7.04, -7.64, -
8.0, -8.30, -8.80), with 6-12 sections per brain as previously described (Loyd et al., 
2007). As the distribution of glial cells was bilaterally symmetrical in the vlPAG, sections 
were sampled unilaterally.  
Morphological Analysis of Microglia Subtype. Microglia morphology is highly 
representative of functional state (Karperien et al., 2013).  Microglia were sampled as 
described above (2-3 representative sections of the caudal ventrolateral PAG (Bregma -
7.64 to -8.3) per animal) and classified into one of three principle morphological 
subtypes: “non-ramified” cells, “intermediate” cells, and “ramified” cells. Non-ramified 
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cells are characterized as having a large circular or oval cell body that is either 
completely amoeboid in shape or with 1 or 2 thick primary processes and no secondary 
processes. Highly ramified “intermediate” cells were characterized as having many 
stout, thick processes arranged in bundles around a large cell body.  “Intermediate” 
cells often have several thick primary processes, extending a relatively short distance 
from the soma; each primary process often has many short secondary processes, 
giving these cells a “bushy” appearance that are very darkly stained with Iba-1. In 
contrast to non-ramified and intermediate cells, highly ramified cells have small round 
cell bodies with many (generally 4-10) long, thin processes. The primary processes of 
highly ramified microglia have few secondary processes, extend a large distance from 
the soma, and are often lightly stained with Iba-1. Representative images of each cell 
type are provided in Figure 2.2.1. Non-ramified and intermediate microglia are 
considered to be “active” or “reactive”, while highly ramified microglia with thin 
processes are considered to be quiescent (Frank et al., 2006; Bland et al., 2010; Colton 
and Wilcock, 2010; Kettenmann et al., 2011; Karperien et al., 2013; Lenz et al., 2013). 
Iba1-positive cells were counted only if the cell body and processes were completely 
visible within the image. Ambiguous cells with processes extending beyond the borders 
of the image, overlapping cells, and cells out of the plane of focus of the image were not 
counted.  
 
Figure 2.2.1. Microglial Subtypes.  
Representative images of the three classifications of microglia based on morphology. “Non-ramified”: 
round/amoeboid activated microglia; “Intermediate”: reactive microglia with numerous thick processes; 
“Ramified” microglia with thin long processes. Scale bars represent 2µm in all images. 
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Data Analysis.  Morphological cell counts were conducted using ImageJ Cell 
Counter tool by three independent investigators blind to treatment and sex of the 
animal. Total number of microglia were also determined to assess changes in microglia 
migration or proliferation. Morphological cell counts, and total microglia number are 
presented as the mean + SEM. Statistical analyses were performed using SPSS 
software (Version 21); data were analyzed using an ANOVA to determine significant 
main effects of sex and treatment on microglia cell counts and morphology. Bonferroni’s 
post hoc test was used to determine a priori specified specific group differences when a 
significant main effect was observed.  p≤0.05 was considered statistically significant. 
 
 Experiment 2: Correlation between microglia activation and morphine ED50 
To determine if there was a relationship between microglia morphological 
subtype and morphine ED50 values, animals (n= 15 males, 8 females) were tested using 
our cumulative dosing paradigm (Morgan et al., 2006; Loyd et al., 2008a; Eidson and 
Murphy, 2013a; Eidson et al., 2016). Briefly, animals received an injection of morphine 
every 20 minutes, resulting in cumulative doses of 1.8, 3.2, 5.6, 8.0, 10.0, and 18 
mg/kg. Control animals received repeated saline injections (1 ml/kg; s.c; n= 6 males, 7 
females). Thermal nociception was assessed using the paw thermal stimulator 15 
minutes after each injection (Hargreaves et al., 1988; Wang et al., 2006; Loyd et al., 
2008b; Eidson and Murphy, 2013a). Briefly, for this test, the rat is placed in a clear 
Plexiglas box resting on an elevated glass plate maintained at 30°C. A radiant beam of 
light is positioned under the hindpaw and the time for the rat to remove the paw from the 
thermal stimulus is electronically recorded as the paw withdrawal latency (PWL) in 
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seconds. A maximal PWL of 20 s was used to prevent tissue damage due to repeated 
application of the noxious thermal stimulus. Animals were acclimated to the testing 
apparatus 30-60 minutes per day for three consecutive days prior to the start of the 
experiment and on the day of testing. All behavioral testing took place between 12:00 
and 17:00 (lights on at 08:00). Temperature of the thermal stimulus was recorded 
before and after each trial to maintain consistent recordings between groups and did not 
exceed 64°C throughout the course of the experiments. All testing was conducted blind 
with respect to group assignment. To calculate ED50, PWL data was normalized using 
GraphPad PRISM software, such that each individual animal’s baseline PWL score = 
0% and 20s = 100%. The normalized data was then plotted and ED50 was calculated as 
the point on the X-axis that corresponds with 50% maximal PWL (Morgan et al., 2006; 
Eidson and Murphy, 2013a; Eidson et al., 2016).  
Immunohistochemistry. Within 60 minutes of the final morphine dose, animals 
were perfused and tissue was collected for immunohistochemical analyses. Microglia 
were categorized in the vlPAG as described above. To determine if morphine’s impact 
on glia morphology was limited to the PAG or represented a more centralized effect, 
microglia were also characterized by morphological type for the following brain regions:  
rostral ventromedial medulla (RVM; Bregma -11.2:-12.2; implicated in pain modulation); 
superior colliculus (Bregma -6.9:-8.2; high MOR density but not implicated in pain); and 
substantia nigra (Bregma -5.0:-5.3; high levels of MOR and implicated in reward and 
addiction). The medial amygdala (Bregma -2.4:-3.0) was also analyzed as this region 
has a high density of microglia, but is not implicated in pain and is devoid of MOR.  
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Data analysis and presentation. Morphine ED50 values were compared between 
males and females using Mann Whitney U Test to confirm replication of previously 
observed sex differences (Loyd et al., 2008b; Loyd et al., 2008a). Analysis of 
covariation between ED50 values and microglial morphological subtype were assessed 
for each sex using SPSS statistical software; p≤0.05 was considered significant.  
 
 Experiment 3: Influence of peripheral endotoxin LPS on microglia response 
in the vlPAG 
To determine if sex differences in microglia activation are driven by morphine or 
reflected a global sex difference in activation, animals received an injection of the TLR4 
agonist lipopolysaccharide (endotoxin LPS; 1 mg/kg, i.p.; Sigma; n=7 males, 6 females) 
or equivolume saline (n= 7 males, 6 females). Comparable doses of peripheral LPS 
have been shown in male rats to increase the proinflammatory cytokine IL-1  mRNA in 
the brain (Buttini and Boddeke, 1995; Nguyen et al., 1998; Quan et al., 1998; Quan et 
al., 1999) and alter microglia morphology (Buttini et al., 1996). LPS-induced febrile 
responses were monitored using Thermocron iButtons (Maxim Integrated, San Jose; 
model DS1921G), implanted into the abdominal cavity 7-10 days prior to testing. Body 
temperature was recorded in 30-minute intervals beginning 6 hours prior to LPS. 
Animals were sacrificed and transcardially perfused six hours following LPS 
administration, when central cytokine mRNA levels peak (Nakamura et al., 1999; Turrin 
et al., 2001; Qin et al., 2007; Czerniawski and Guzowski, 2014). Tissue was collected 
and processed for visualization of microglia (Iba-1) as described above. Iba-1 levels 
were analyzed for the PAG, RVM, SC, SN, and MeA.  A subset of animals were 
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sacrificed by decapitation and their brains flash frozen for determination of cytokine 
levels using qPCR as previously described (Eidson et al., 2016). 
Examination and presentation of immunomodulatory cytokines using qPCR. 
Flash frozen brains were sectioned at 300 μm on a cryostat (Leica) and mounted onto 
slides. One-millimeter bilateral micropunches were taken from 6 levels of the vlPAG 
(Bregma -6.72, -7.04, -7.64, -8.0, -8.30, -8.80) and RNA was extracted with TRIzol (Life 
Technologies; 15596026) using standard procedures, followed by the addition of 
Glycoblue (Life Technologies; AM5916) for visualization. Concentrations of RNA (ng/µl) 
were calculated using a NanoDrop ND-1000 Spectrophotometer (Version 3.8, Thermo 
Fisher; DE). Following RNA extraction, RNA was diluted to a standard concentration 
and converted to cDNA using an AMV First-Strand Synthesis Kit (Invitrogen). PCR was 
performed using FastStart Essential DNA Green MasterMix (Roche) and analyzed using 
a Roche LightCycler 96 and accompanying software (Version 1.1.0.1320, 2011 Roche 
Diagnostics; Switzerland). Data are presented as the normalized ratio of the target 
gene, with corrected amplification efficiency, relative to the GAPDH control gene. Primer 
sequences can be found in Table 1.  
Data Analysis. The impact of sex and treatment on microglia morphology and 
cytokine mRNA levels were analyzed using an ANOVA, with Bonferroni post-hoc 
analysis where appropriate. Differences between males and females were compared 
using independent t-tests when k=2. Body temperature data were analyzed for 
significant main effects of sex and treatment across time using a mixed model ANOVA 
with Greenhouse-Geisser correction. Body temperature data are presented as the 
difference between saline-treated groups at 1-hour intervals post-LPS. Density, 
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morphology, and PCR data are presented as Cq means ±SEM; p≤0.05 was 
considered significant. 
 
Table 1 Chapter 2 Primer Sequences for qPCR of Inflammatory Markers 
GAPDH 
Forward GAG GTG ACC GCA TCT TCT TG 
Reverse CCG ACC TTC ACC ATC TTG TC 
IL-1β 
Forward CCC TGA AGG ATG TGA TCA TTG 
Reverse GGC AAA GGG TTT CTC CAC TT 
IL-6 
Forward AAG ACC CAA GCA CCT TCT TT 
Reverse AGA CAG CAC GAG GCA TTT TT 
IL-10 
Forward TGT ACC TTA TCT ACT CCC AGG TTC TCT 
Reverse GTG TGG GTG AGG AGC ACG TA 
TNF 
Forward TGT ACC TTA TCT ACT CCC AGG TTC TCT 
Reverse GTG TGG GTG AGG AGC ACG TA 
TLR4 
Forward TCC CTG CAT AGA GGT ACT TC 
Reverse CAC ACC TGG ATA AAT CCA GC 
 
 Experiment 4: Effect of TLR4 manipulation on morphine analgesia  
Intra-vlPAG cannulae implantation. To determine if PAG TLR4 activation or 
inhibition impacted morphine analgesia, animals were anesthetized to a deep surgical 
plane with 5% isoflurane (maintained at 2–5% isoflurane throughout surgery; Henry 
Schein Animal Health) and bilateral guide cannulae (22 gauge; Plastics One) aimed at 
the vlPAG (anterior—posterior: 1.7 mm; mediolateral: ±0.6 mm; dorsoventral: −5.0 mm 
from lambda) were implanted stereotaxically as previously described (Loyd et al., 
2008a; Eidson and Murphy, 2013a). Animals were allowed to recover a minimum of 10 
days post-cannula implantation before behavioral testing. Injection cannulae were 
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inserted into guide cannulae once a day for three days prior to testing to acclimate the 
animals to the injection procedure and maintain cannulae patency. Animals with blocked 
cannula were retained as no injection controls. No significant differences were observed 
between non-injected animals (n= 2 males, 5 females) and those animals receiving 
intra-PAG saline, so these groups are collapsed (data not shown).  
Experiment 4.1: Effects of TLR4 agonism on morphine analgesia. On the day of 
testing, male and female rats received a single intra-PAG injection of LPS (5.0 μg/0.5 
μl/side; Sigma) or saline (0.5 μl/side) into the PAG. This dose has been previously 
shown to increase glial activation and cytokine expression (Castano et al., 2002; 
Hernandez-Romero et al., 2008; Eidson and Murphy, 2013a). One hour later, morphine 
ED50 values were determined using the cumulative dosing paradigm described in 
Experiment 2. A total of 4 treatment groups were generated: Saline+Saline (n=5 males, 
5 females), LPS+Saline (n=5 males, 5 females), Saline+Morphine (n=8 males, 11 
females), and LPS+Morphine (n=7 males, 8 females).  
Experiment 4.2: Effects of TLR4 antagonism on morphine analgesia. On the day 
of testing, animals received a single intra-PAG injection of (+)-naloxone (5.0 μg/0.5 
μl/side; NIDA) or saline (0.5 μl/side); one hour later morphine ED50 values were 
determined as described above. This dose was chosen based on our previous 
experiments demonstrating inhibition of PAG microglia (Eidson and Murphy, 2013a). A 
total of 4 treatment groups were generated: Saline+Saline (n=5 males, 5 females), 
Naloxone+Saline (n=5 males, 5 females), Saline+Morphine (n=8 males, 11 females), 
and Naloxone+Morphine (n=7 males, 9 females).  
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Data analysis and presentation. At the end of the experiment, brains were 
removed, flash frozen, and sectioned at 25 μm with a Leica CM3050S cryostat. 
Sections from the injection site were mounted on to slides, Nissl stained, coverslipped, 
and cannulae placement verified using a Nikon microscope (10X magnification). 
Animals with bilateral cannulae located outside of the vlPAG (e.g., in the aqueduct or 
deep mesencephalic nucleus) were considered “cannulae misses” and analyzed for 
determination of site specificity.  
Half-maximal antinociceptive effect (ED50) and 95% confidence intervals (CI) 
were calculated from dose–response curves generated using Graph-Pad PRISM 
software as described above. Repeated measures ANOVA was used to assess for 
significant treatment effects, with Bonferroni’s post hoc tests where appropriate. 
Cannula misses were compared to “hits” using a two-tailed Wilcoxon signed-rank test. 
Values of p≤0.05 were considered statistically significant. 
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 Results 
 Experiment 1: Sex, but not morphine treatment, affects microglia activation 
in the vlPAG 
Male and female rats were administered morphine or saline, and microglia were 
examined immunohistochemically within the caudal vlPAG at 15, 30, and 60 minutes 
post-injection. A separate group of rats served as handled controls. No significant effect 
of time post-injection was noted in microglia morphology for either the saline or 
morphine treated groups so these data are collapsed across time. Additionally, no 
significant differences were observed in total microglia cell counts in the PAG, 
regardless of sex (F(1,68)=0.013, p= 0.91) or treatment (F(1,68)=0.13, p= 0.720; Figure 
2.3.1a).  
Overall, females had significantly more non-ramified and intermediate type 
microglia in the vlPAG that was independent of treatment (F(1,76) =  13.10, p= 0.01; 
Figure 2.3.1b). We next determined if the observed sex difference in percentage of 
activated microglia was specific for a morphological subtype (non-ramified, intermediate 
or ramified; see Figure 2.3.1). The percentage of both non-ramified (t= 3.10, p< 0.001) 
and intermediate (t= 2.17, p= 0.03) microglia was significantly higher in females than 
males (Figure 2.2c). Females also had significantly fewer ramified microglia than males 
(t= 3.90, p< 0.001). Together, these data indicate that although there are no sex 
differences in the overall number of vlPAG microglia, the ratio of non-ramified and 
intermediate to ramified microglia are significantly greater in females than males, 
regardless of treatment. 
35 
 
 
Figure 2.3.1. Sex, but Not Morphine Treatment or Time, Affects Microglia Activation in the vlPAG. 
(a) No significant differences in microglia cell number were noted as a function of sex, time (collapsed) or 
treatment (handled [n= 5 males, 6 females], saline [n= 15 males, 17 females], morphine [n= 22 males, 17 
females]). (b) Females had significantly more non-ramified/amoeboid [NR] and intermediate [I] microglia 
than males regardless of treatment (t(80)=3.90, p<0.001). As shown in the scatterplot at right, the 
percentage of non-ramified/amoeboid [NR] and intermediate [I] microglia were highly variable within each 
sex (line indicates median). (c) Females had significantly more non-ramified [NR] and intermediate [I], and 
fewer ramified [R] microglia in the vlPAG than males. 
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 Experiment 2: Microglial activation in the PAG correlates with morphine 
ED50. 
PAG or spinal cord activation of microglia has been shown to oppose morphine 
analgesia (Watkins et al., 2005; Hutchinson et al., 2010; Eidson and Murphy, 2013b, a); 
therefore, we next examined the degree of association between morphine ED50 values 
and PAG microglia morphology for males and females. Animals were administered 
cumulative doses of morphine and sacrificed within sixty minutes of the final injection of 
morphine; microglia morphology was determined immunohistochemically. Consistent 
with our previous studies (Loyd et al., 2008b; Loyd et al., 2008a), ED50 values were 
significantly higher in females than males (female, 8.69 vs. male, 6.01 mg/kg; U = 30.5, 
p= 0.028), and no relationship was observed between ED50 and female estrus cycle (r= 
0.19, p= 0.19). Morphine ED50 values were significantly correlated with the percentage 
of non-ramified and intermediate microglia, morphologies typical of “activated” microglia, 
in the vlPAG in both males (r=0.58, p=0.02) and females (r=0.68, p=0.047; Figure 
2.3.2a).  Further analysis by microglia morphological subtype showed no significant 
correlation for non-ramified microglia and morphine ED50 in males (r= 0.47, p= 0.051) or 
females (r= 0.32, p= 0.24). Intermediate microglia correlated significantly with ED50 in 
females (r= 0.679, p= 0.047) but not males (r= 0.316, p= 0.15), and ramified microglia 
negatively correlated with ED50 in both males (r= -0.58, p= 0.02) and females (r= -0.68, 
p= 0.047; Figure 2.3.2b). Together, these data show sex-specific positive correlations 
between morphine ED50 and percentage of activated microglia, and reciprocal negative 
correlations with morphine ED50 and ramified microglia, such that as the percent of 
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ramified microglia decreases, morphine ED50 increases (i.e. morphine is less 
efficacious).  
We next determined if the relationship between microglia morphology and 
morphine ED50 values was specific to the PAG, or extended to regions also implicated 
in pain (RVM), and/or regions with high levels of MOR (SN, SC) or a high density of 
microglia (MeA). For females, no significant correlation between morphine ED50 and the 
percentage of non-ramified and intermediate microglia were observed in RVM (r= 0.21, 
p= 0.32), amygdala (r= 0.48, p= 0.12), superior colliculus (r= -0.05, p= 0.46), or 
substantia nigra (r= 0.09, p= 0.44). Similarly, in males, no significant correlations were 
observed in the RVM (r= -0.13, p= 0.35), amygdala (r= 0.23, p= 0.24), or substantia 
nigra (r= 0.32, p= 0.20). However, significant correlations between morphine ED50 and 
percentage of non-ramified and intermediate microglia were noted in superior colliculus 
of male rats (r= 0.53, p= 0.05; Figure 2.3.2c-g).  
Similar to what was observed for the PAG, no significant differences were 
observed in the total number of microglia in any of the brain regions examined (F(3,28)= 
0.152, p= 0.93; data not shown), indicating that the difference in the number of activated 
cells between males and females is not due to increased proliferation or migration of 
activated microglia. Rather, these data indicate that morphine ED50 positively correlates 
with the overall percent of non-ramified and intermediate microglia, states typical of 
activation, in the PAG in males and females, with sex-specific differences in correlations 
noted for the superior colliculus. 
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Figure 2.3.2. Percent Activated Microglia Correlate with Morphine Effective Dose.  
Bivariate correlations of morphine ED50 for the percentage of (a) total non-ramified and intermediate 
microglia and (b) by morphological subtype within the PAG. Degree of relatedness for morphine ED50 and 
microglia morphology are also shown for the (c) amygdala, (d) rostral ventral medulla, (e) superior 
colliculus, and f) substantia nigra. n= 15 males, 8 females. 
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 Experiment 3a: Immune Challenge Activates vlPAG Microglia to a Greater 
Extent in Females than in Males 
The results from the above experiment show that although there were 
significantly more microglia with a non-ramified or intermediate morphology in females 
than males, these microglia were unaffected by morphine treatment.  Therefore, we 
next tested if administration of LPS, a TLR4 agonist, activated vlPAG microglia in a sex-
dependent manner. Peripheral administration of LPS induced a significant increase in 
the percent of non-ramified and intermediate microglia in the vlPAG of females (19%), 
but not males (12%; Figure 2.3.3a); significant main effect of sex (F(1,22)=18.26, p< 
0.001) and treatment (F(1,22)= 11.84, p< 0.001). Similar to what was noted in Experiment 
1, females had more non-ramified and intermediate microglia in the PAG at baseline 
(p=0.03).  
Analysis of microglia by morphological subtype showed a significant main effect 
of both sex (F(2, 44)= 13.14, p= 0.001) and treatment (F(2,44) = 6.44, p= 0.001) on 
microglia morphology and no interaction (F(2,44)= 0.55, p= 0.58). Specifically, saline 
treated females had significantly more intermediate (t= 2.43, p= 0.05), and significantly 
fewer ramified (t= 2.83, p= 0.03) microglia than saline males. Similarly, LPS-treated 
females have significantly more intermediate (t= 2.95, p= 0.01), and significantly fewer 
ramified (t= 3.10, p= 0.01) microglia than LPS males (Figure 2.3.3b), suggesting a more 
“activated” morphological state in females. The observed sex difference in microglia 
morphology in the PAG was not accompanied by differences in sickness behaviors as 
no sex differences in core body temperature were observed in animals treated with LPS 
(F(1,13)=2.22, p= 0.16; Figure 2.3.3d). These data suggest that in females, PAG microglia 
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may be more responsive to TLR4 activation (i.e. lower threshold) than their male 
counterpart.  
No significant main effects of sex on total number of non-ramified and 
intermediate microglia were observed in any other brain region examined (Figure 
2.3.3e). In contrast to what was noted with morphine, main effects of LPS-treatment 
were observed in several brain regions, including the superior colliculus (F(1,20)=10.862, 
p< 0.001) in males (p= 0.01) but not females (p=0.08), and the RVM (F(1,15)=5.76, p= 
0.03) in males (p= 0.03) but not females (p= 0.32). No significant main effects of LPS 
treatment were observed in the amygdala or substantia nigra, and no interaction effects 
were observed in any brain region tested. Finally, no significant differences were 
observed in the total number of microglia in any brain regions examined (data not 
shown). 
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Figure 2.3.3. Treatment with TLR4 Agonist Lipopolysaccharide Increases Microglia Activation in Females.  
(a) LPS induces greater proportions of non-ramified/amoeboid [NR] and intermediate [I] microglia in the 
PAG of females than males. (b) LPS-treated females had a higher percent of intermediate (I) microglia in 
the vlPAG than saline-treated females and show decreased percent of ramified (R) microglia compared 
with all other groups. (c) Representative images of microglia in the vlPAG of an LPS-treated male and 
female. Note that females have a greater density of non-ramified and intermediate microglia than males. 
Scale bar = 5µm. (d) No sex differences in febrile response were noted following LPS administration. (e) 
Percentage of non-ramified and intermediate microglia for males and females following saline or LPS 
administration. LPS-induced increases in activated microglia were region- and sex-dependent. Endotoxin 
LPS, n=7 males, 6 females; saline, n= 7 males, 6 females. 
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 Experiment 3b: Immune challenge induces greater cytokine expression in 
the vlPAG of females 
To determine if the observed sex differences in PAG microglia morphology was 
accompanied by sex-specific differences in proinflammatory cytokine transcription, 
qPCR was used to quantify PAG mRNA levels of pro-inflammatory TNF, IL-1β, IL-6, and 
anti-inflammatory IL-10 (Figure 2.3.4). LPS induced a significant increase in vlPAG TNF 
transcription in both males (p < 0.001) and females (p < 0.001) compared with saline 
controls (F(1,42)= 50.72, p< 0.001). LPS treatment also induced in a significant increase 
in IL-1β transcription in females (p<0.001) and males (p<0.001); significant main effect 
of treatment (F(1,38) = 47.08, p= 0.00). Notably, IL-1β levels were significantly higher in 
LPS treated females than males (p=0.03). LPS did not significantly change IL-6 in either 
sex (F(1,34)= 0.19, p= 0.67). PAG transcription of the anti-inflammatory cytokine IL-10 
was significantly higher in males than in females (F(1,44)= 14.99, p< 0.001). LPS induced 
a significant decrease in IL-10 mRNA in females (t=3.33, p< 0.001) but not males (t=-
0.19, p=0.86; Figure 2.3.4e). Together, these data demonstrate that PAG TLR4 
activation induces an exaggerated pro-inflammatory response and a reduced anti-
inflammatory response in females compared with males. Furthermore, these data 
support our immunohistochemical studies demonstrating that changes in microglial 
morphology are accompanied by measurable changes in pro-inflammatory cytokine 
mRNA.  
We also examined LPS induced changes in PAG TLR4 transcription. LPS 
administration increased TLR4 transcription by 67% in females and 39% in males, 
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however these differences were not statistically significant: treatment, F(1,40)= 2.37, p= 
0.13;  sex, F(1,40)= 2.37, p= 0.13.  
 
 
 
Figure 2.3.4. LPS-induced Changes in Cytokine and TLR4 Transcription in the vlPAG of Males and 
Females.  
Peripheral administration of LPS increased the transcription of (a) TNF and (b) IL-1β in the vlPAG. No 
change in IL-6 was noted (c). Transcription of the anti-inflammatory cytokine IL-10 significantly decreased 
in females following LPS (d). No differences in TLR4 transcription (e) were noted for sex or treatment. 
Endotoxin LPS, n=5 males, 5 females; saline, n= 3 males, 3 females. 
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 Experiment 4. Manipulation of PAG TLR4 signaling has sex-dependent 
effects on morphine ED50 values 
Our previous studies established a direct link between microglia activation and 
morphine efficacy, such that site specific administration of the TLR4 agonist LPS 
resulted in a significant reduction in morphine efficacy (as indicated by a rightward shift 
in the morphine dose-response curve (Eidson and Murphy, 2013a). Given the results of 
the present experiments demonstrating that females show more non-ramified and 
intermediate morphologies than males, we next examined if this sex difference in 
microglia morphology would result in a sexually dimorphic shift in morphine ED50. In 
particular, we tested if activation of vlPAG TLR4 via site specific administration of the 
endotoxin LPS would result in a larger rightward shift in the morphine dose-response 
curve in females compared with males. We further examined if blockade of TLR4 
signaling with (+)-naloxone would result in a greater leftward shift of the morphine dose-
response curve in females, indicative of potentiation of morphine antinociception in 
females.  
Intra-PAG administration of LPS resulted in a significant decrease in morphine 
antinociception in both males and females, as indicated by a significant rightward shift in 
the morphine ED50 dose-response curve (F(5,30) = 18.01, p< 0.0001; Figure 2.3.5a). LPS 
increased male ED50 values from 3.04 to 10.69 mg/kg, a 3.5 fold difference, p< 0.001; 
female ED50 values increased from 7.9 to 20.61 mg/kg, a 2.6 fold difference, p< 0.05. 
ED50 values were approximately two-fold higher in LPS+Morphine females than males 
(20.61 in females vs. 10.69 mg/kg in males; p> 0.05). Remarkably, following LPS 
priming, 6/8 females continued to respond at baseline levels following morphine 
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administration at 10 mg/kg; 2 of those 6 females responded near baseline following the 
18 mg/kg dose. Indeed, females in the LPS+Morphine treated groups were not 
significantly different from saline control females that received no morphine 
(Saline+Saline females; p>0.05), indicating that LPS pre-treatment completely 
abolished the antinociceptive effects of morphine in a subset of females. No differences 
in response latencies were observed between LPS+Morphine males and 
Saline+Morphine females (p> 0.05), indicating that LPS activation of microglia reduced 
males to ‘female-typical’ levels of analgesia.  
No sex differences were observed between Saline+Saline treated males and 
females (p> 0.05), and no significant differences were observed between LPS+Saline 
and Saline+Saline males (p> 0.05) or females (p>0.05), indicating LPS administration 
alone had no effect on basal PWL, consistent with what we have previously observed 
(Eidson and Murphy, 2013a). Together, these results indicate that microglia activation 
with LPS significantly decreases, or completely abolishes (in 33% of females), the 
antinociceptive effects of morphine.  
We next determined if blocking microglia activation with the TLR4-specific 
antagonist (+)-naloxone potentiated morphine analgesia in a sex-dependent manner. In 
animals treated with morphine, intra-PAG administration of (+)-naloxone significantly 
increased antinociception in females, but not males, as indicated by a leftward shift in 
the morphine dose response curve (F(3,18) = 13.67, p<0.0001; Figure 2.3.5b). 
Specifically, ED50 values for females treated with (+)-naloxone decreased from 7.9 
mg/kg to 3.16 mg/kg (p< 0.001), a 2.5-fold reduction in ED50. Importantly, ED50 values 
for (+)-naloxone+Morphine treated females are not significantly different from 
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Saline+Morphine treated males (p> 0.05), indicating that blocking microglia activation 
within the vlPAG completely abolishes sex differences in morphine analgesia. A 
moderate, but significant, increase in morphine ED50 was observed in males receiving 
(+)-naloxone+Morphine compared with Saline+Morphine males (ED50 increased from 
3.04 mg/kg vs. 5.25 mg/kg; p< 0.05).  
No sex differences between Saline+Saline treated males and females (p> 0.05) 
was observed. In addition, we observed no significant differences between (+)-
naloxone+Saline and Saline+Saline controls in males (p> 0.05) or females (p> 0.05) 
indicating (+)-naloxone administration has no effect on basal nociceptive thresholds. 
The effects of (+)-naloxone on morphine analgesia are site-specific; male and female 
animals receiving (+)-naloxone outside the PAG showed significantly lower morphine 
antinociception relative to animals that received (+)-naloxone within the PAG (F(3,18) = 
15.17, p<0.001; data not shown).  Together, these data indicate inhibition of vlPAG 
microglia activity with the TLR4-specific antagonist (+)-naloxone is sufficient to reverse 
sex differences in morphine analgesia.  
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Figure 2.3.5. Pharmacological Blockade or Activation of vlPAG Microglia has a Sex-dependent Impact 
on Morphine Antinociception.  
(a) LPS-induced activation of vlPAG microglia significantly attenuates the antinociceptive effects of 
morphine in both males and females, as indicated by a significant rightward shift in the morphine dose 
response curve. Saline+Saline (n=5 males, 5 females), LPS+Saline (n=5 males, 5 females), 
Saline+Morphine (n=8 males, 11 females), and LPS+Morphine (n=7 males, 8 females). (b) In contrast, 
inhibition of TLR4 via intra-vlPAG (+)-naloxone results in a significant leftward shift in morphine dose-
response curves in females, such that (+)-naloxone + Morphine-treated females are not significantly 
different from Saline + Morphine-treated males. Naloxone+Saline (n=5 males, 5 females), 
Naloxone+Morphine (n=7 males, 9 females).  
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 Discussion  
Here we test the hypothesis that sex differences in vlPAG microglia contribute to 
the sexually dimorphic effects of morphine. We report that although no sex differences 
in overall number or density of microglia were noted for the vlPAG at baseline, the 
percentage of non-ramified and intermediate versus “ramified” microglia were 
significantly higher in females than males, suggesting that females have a more 
'activated” microglial state within the vlPAG. Consistent with our previous studies, 
morphine ED50 values were significantly higher in females (Loyd et al., 2008b; Loyd et 
al., 2008a) , and a significant relationship was observed between morphine potency and 
percentage of reactive “intermediate” microglia in females, but not males. Although 
acute morphine treatment did not change microglia morphology in either sex, 
administration of the glial TLR4 agonist LPS increased the percentage of non-ramified 
and intermediate microglia in the vlPAG of females to a greater degree than males, an 
effect that was independent of febrile response. The LPS induced increases in microglia 
activation in females was accompanied by significantly increased proinflammatory IL-1β 
transcription and decreased anti-inflammatory IL-10 transcription. We further show that 
priming microglia with LPS significantly attenuates morphine analgesia in both sexes, 
and completely abolishes the antinociceptive response to morphine in a subset of 
females. Similarly, inhibition of vlPAG microglia with the TLR4 antagonist (+)-naloxone 
significantly potentiates morphine analgesia in females, but not males, abolishing the 
sex difference in opiate response. Together, these data indicate that vlPAG microglia 
are innately different in males and females in terms of their morphological state (both 
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basal and following immune activation with LPS), and implicate TLR4 in the attenuated 
response to morphine observed in females.  
These studies are the first to implicate vlPAG microglial TLR4 in sex differences 
in morphine analgesia, and suggest that increased activation of vlPAG microglia 
contribute to the attenuated response to morphine observed in females. Importantly, 
these experiments establish that inhibition of vlPAG TLR4 in females reverses the 
observed sex differences in morphine analgesia. Together, these data suggest novel 
methods to improve current morphine-based pain management via inhibition of TLR4, 
and illustrate the necessity for sex-specific research and individualized treatment of pain 
in men and women. 
 Sex differences in morphine analgesia and TLR4  
Preclinical studies utilizing orofacial, somatosensory or visceral pain assays 
typically report that morphine produces a significantly greater degree of analgesia in 
males versus females (Craft, 2003; Craft et al., 2004; Ji et al., 2006; Wang et al., 2006; 
Loyd et al., 2008a). Consistent with the present results, these studies also report 
morphine ED50 values that are 2-fold higher in females than in males.  The present 
studies demonstrate that sex differences in PAG microglia, and in particular TLR4 
signaling, contribute to the dimorphic response to morphine. TLR4 signaling has been 
previously shown to modulate morphine action in males (Tanga et al., 2005; Hutchinson 
et al., 2007; Hutchinson et al., 2008b; Hutchinson et al., 2008a), such that TLR4 
activation with LPS reduces morphine efficacy (Johnston and Westbrook, 2005). The 
present studies confirm these previous findings in males, and further demonstrate that 
initiation of TLR4 signaling significantly, and almost completely, attenuates morphine 
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analgesia in females. In addition, blockade of vlPAG TLR4 increases the analgesic 
efficacy of morphine in females (2.5-fold reduction in morphine ED50), reversing the 
observed sex difference in morphine response.   
Several factors have been shown to contribute to the sexually dimorphic 
response to morphine. Interestingly, these factors are also heavily impacted by 
microglia. For example, blockade of N-methyl-d-aspartate (NMDA) signaling inhibits 
microglia activation (Thomas and Kuhn, 2005; Murugan et al., 2011) and enhances the 
antinociceptive effects of morphine to a greater degree in male than female rats 
(Holtman et al., 2003). Sex differences in MOR expression and signaling in the PAG 
(Bernal et al., 2007; Loyd et al., 2008a), as well as spinal MOR:KOR dimerization 
(Chakrabarti et al., 2010), have also been shown to contribute to the dimorphic effects 
of morphine.  MOR expression is rapidly upregulated following peripheral inflammation 
and cytokine release in male rats (Ji et al., 1995; Mousa, 2003; Puehler et al., 2004), 
likely a homeostatic response that counteracts the excitatory effects of glial activation 
and thereby increases opioid efficacy. Interestingly, no change in MOR expression is 
noted in female rats following peripheral inflammation (Zhang et al., 2014), which may 
also contribute to the reduced antinociceptive effects of morphine observed in persistent 
pain assays (Cook and Nickerson, 2005; Loyd and Murphy, 2006; Wang et al., 2006; 
Murphy et al., 2009). We speculate that NMDAR and MOR activity represent 
downstream or parallel targets of microglia activation, and may explain the existence of 
multiple mechanisms underlying the sexually dimorphic response to morphine.  
Sex-specific differences in TLR4 modulation of pain have been previously 
reported (Sorge et al., 2011; Sorge et al., 2015b). For example, in mice, inhibition or 
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transient depletion of spinal microglia reverses mechanical allodynia induced by spared 
nerve injury in males, but not females, suggesting that spinally-mediated chronic pain in 
females is maintained in a non-TLR dependent manner (e.g. an adaptive immune-
dependent response) (Sorge et al., 2015a). In the present study, chronic pain was not 
induced; rather, LPS was administered to activate microglia in a TLR4-dependent 
manner. Sex-specific effects of TLR4 activity exemplify the need to consider both sexes 
when studying immune responses and the development of drugs impacting immune 
signaling. As TLR4 has also been shown to mediate the rewarding effects of morphine 
(Hutchinson et al., 2012) and the development of tolerance to morphine (Eidson and 
Murphy, 2013b; Eidson et al., 2016), sex differences in TLR4 signaling may have broad 
implications for the treatment of chronic pain in men and women.  
 Sex differences in innate immune function 
In the present study, we show that female rats have significantly more “activated” 
microglia in the PAG than males at baseline, a difference that is potentiated following 
systemic LPS treatment. This finding suggests that females have a lower threshold for 
activation and/or launch a more robust proinflammatory response compared with males. 
Indeed, females of many species launch a more robust immune response than males 
(Gaillard and Spinedi, 1998; Klein, 2000; Schwarz and Bilbo, 2012). For example, in the 
peripheral immune system, female mice have higher titers of immunoglobulins (Klein, 
2000) and splenocyte blastogenic responses to T and B cell mitogens than males 
(Schneider et al., 2006). Females often present with greater levels of pro-inflammatory 
markers following immune challenge (Tonelli et al., 2008; Bollinger et al., 2016; 
Morrison and Filosa, 2016). Interestingly, despite increases in PAG microglia activation 
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and IL-1β release in response to LPS immune challenge in females, we observed no 
sex differences in LPS-induced febrile response. However, IL-6, which correlates most 
closely with changes in body temperature (LeMay et al., 1990; Roth et al., 1993; Roth 
and De Souza, 2001), was not different in males and females, and may account for the 
lack of observed sex difference in fever response. 
The present experiments used normally cycling female rats. Estrus cycle was 
monitored, but not controlled or manipulated, to demonstrate physiologically relevant 
changes in microglia activation as a function of estrus cycle. No significant effect of 
estrus cycle was observed in any of the present experiments. Immunomodulatory 
effects of sex hormones, specifically estradiol, have been shown to alter cytokine 
release and microglial activation in a concentration-, age-, and duration-dependent 
manner. For example, uterine TNF, IL-1β, and IL-6 levels increase during proestrus and 
estrus in rats (De et al., 1992), when estradiol is high. This coincides with our previous 
data demonstrating that morphine is least effective in reducing nociception during 
proestrus (Loyd et al., 2008a). Historically, estradiol is thought to be neuroprotective, 
but these effects may be biphasic (Whitacre et al., 1999) such that high levels of 
estradiol decrease inflammatory markers and attenuate the inflammatory response to 
LPS (Dimayuga et al., 2005), while low doses, comparable to normal circulating levels, 
increase concentrations of proinflammatory cytokines (Correale et al., 1998). 
Furthermore, chronic but not acute estradiol administration increases pro-inflammatory 
responses in peripheral immune cells of females compared with males (Calippe et al., 
2008; Calippe et al., 2010), and potentiates LPS-evoked TLR4 immune responses in 
vitro (Loram et al., 2012). Consistent with clinical research demonstrating that women 
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have a much higher incidence rate of autoimmune disorders and chronic inflammatory 
conditions such as migraine (Buse et al., 2013), osteo- and rheumatoid arthritis 
(Whitacre, 2001) compared with men, these results suggest that women may have 
increased susceptibility to immune challenge and are at a greater risk for developing 
inflammatory pathologies than men.  
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Abstract 
Preclinical studies report that the effective dose for morphine is approximately 2-
fold higher in females than males. Following systemic morphine administration, 
morphine is metabolized via Phase II glucuronidation in the liver and brain into two 
active metabolites: morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G), 
each possessing distinct pharmacological profiles. M6G binds to μ opioid receptors and 
acts as a potent analgesic. In contrast, M3G binds to TLR4, initiating a 
neuroinflammatory response that directly opposes the analgesic effects of morphine 
and M6G. M3G serum concentrations are 2-fold higher in females than males, however, 
sex-specific effects of morphine metabolites on analgesia and glial activation in vivo 
remain unknown. The present studies test the hypothesis that increased M3G, and 
subsequent TLR4-mediated activation of glia, is a primary mechanism driving the 
attenuated response to morphine in females. We demonstrate that intra-PAG M6G 
resulted in a greater analgesic response in females, with females requiring less than 
half the dose to achieve maximal analgesia relative to males. In contrast, intra-PAG 
M3G administration significantly attenuated the analgesic effects of systemic morphine 
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in males only, increasing the effective dose of morphine two-fold (5.0 vs 10.3 mg/kg). 
Together, these data implicate sex differences in morphine metabolism, specifically 
M3G, as a contributing factor in the attenuated response to morphine observed in 
females. 
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 Introduction 
Opioids such as morphine are widely used for the treatment of severe pain, with 
3-5% of adults in the US receiving long-term opioid therapy (Dowell et al., 2016). 
Preclinical studies using both acute and chronic pain assays report that morphine is less 
effective in females than in males (Dawson-Basoa and Gintzler, 1993; Mogil et al., 
2000; Craft et al., 2008; Loyd et al., 2008a). Indeed, greater antinociception is observed 
in male rats for almost every opioid tested (Barrett et al., 2002; Terner et al., 2003; 
Stoffel et al., 2005; Peckham and Traynor, 2006; Bai et al., 2015).  
The midbrain periaqueductal gray (PAG) is a key neural locus for opioid action 
(Morgan et al., 2005; Loyd et al., 2007). Direct PAG administration of morphine induces 
long-lasting analgesia, while intra-PAG administration of the opioid antagonist (-)-
naloxone or lesions of PAG μ opioid receptor (MOR) completely abolish the 
antinociceptive effects of systemic morphine (Loyd et al., 2008a). Sex differences are 
also evident following intra-PAG administration of morphine, with the half-maximal 
antinociceptive dose (ED50) in males ranging from 1.2-1.6 µg/µl, while in females ED50 
values range from 16 to >50 µg/µl (Krzanowska and Bodnar, 1999; Loyd et al., 2008a; 
Bobeck et al., 2009).  
Recent data suggest that the innate immune receptor, toll-like receptor 4 (TLR4), 
contributes to the sexually dimorphic effects of morphine (Doyle et al., 2017). Many 
opioids, including morphine, bind to myeloid differentiation factor 2 (MD-2), a co-
receptor of TLR4, located on glial cells (Hutchinson et al., 2010). Although the classical 
μ opioid receptor (MOR) binds only the (-)-stereoisomer of opioids, TLR4 binds opioids 
in a non-stereoselective manner (i.e., both the (-) and (+) isomers of opioid ligands 
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modulate glial signaling) (Hutchinson et al., 2010). TLR4 activation initiates an 
inflammatory response that is characterized by the release of inflammatory compounds 
including cytokines (tumor necrosis factor alpha [TNF], interleukins [IL-1β, IL-6, IL-10]), 
chemokines (CXCL3) and prostaglandin E2 (PGE2) (Bonizzi and Karin, 2004; Doyle 
and O'Neill, 2006; Hutchinson et al., 2008c; Hutchinson et al., 2010). These 
inflammatory factors increase neuronal excitability, resulting in hyperalgesia (Ogoshi et 
al., 2005; Stellwagen et al., 2005; Yan et al., 2014; Eidson et al., 2016) and 
paradoxically reducing the analgesic efficacy of morphine (Hutchinson et al., 2007; 
Hutchinson et al., 2010; Franchi et al., 2012; Li, 2012; Eidson et al., 2016). Our previous 
research demonstrates that inhibition of TLR4 in the vlPAG with the TLR4-specific 
antagonist (+)-naloxone potentiates analgesia in females and abolishes the sex 
difference in morphine response (Doyle et al., 2017). 
Recent studies suggest that morphine’s primary metabolites contribute 
significantly to its immunomodulatory effects (Lewis et al., 2010; Grace et al., 2014). 
Following administration, ~90% of morphine is metabolized primarily in the liver 
(Coffman et al., 1997), as well as peripheral macrophages (Tochigi et al., 2005) and 
brain microglia (Togna et al., 2013), to form two active glucuronide metabolites: 
morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G), each with distinct 
pharmacological properties (Coughtrie et al., 1989; Christrup, 1997). M6G binds to 
MOR with high affinity, and is a potent analgesic (Abbott and Palmour, 1988; Wittwer 
and Kern, 2006). M3G, on the other hand, does not bind to MOR and does not produce 
analgesia (Loser et al., 1996). Rather, M3G binds with high affinity to TLR4 (Lewis et 
al., 2010; Due et al., 2012) to upregulate pro-inflammatory IL-1 in vitro, induce allodynia 
58 
and hyperalgesia, and actively opposes the analgesic effects of morphine and M6G 
(Smith et al., 1990; Ekblom et al., 1993; Bartlett et al., 1994; Angst and Clark, 2006; 
Juni et al., 2006; Lewis et al., 2010). Importantly, unlike the vast majority of opioids, 
M6G does not bind to TLR4 and is not associated with a pro-inflammatory response 
(Carrigan and Lysle, 2001; Hutchinson et al., 2010).  
Several studies in rats have observed sex differences in morphine metabolism, 
such that morphine administration results in approximately two-times greater 
concentrations of M3G in the plasma of females compared with males (Baker and 
Ratka, 2002; South et al., 2009). Though M3G concentrations are higher in females, 
there is no direct evidence that the increased M3G:M6G ratio contribute to the reduced 
efficacy of morphine observed in females. The present studies test the hypothesis that 
M3G specifically contributes to the observed sex differences in morphine 
antinociception by activating TLR4 and opposing morphine analgesia to a greater 
degree in females. Most importantly, the present studies investigate whether MOR 
activation with M6G, in the absence of morphine/M3G-induced glial activation, ultimately 
leads to equipotent analgesia in both males and females.  
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 Materials and methods  
 General methods 
Subjects. Age and weight matched (60-90 day old; 250-400g) intact male and 
normally cycling female Sprague Dawley rats (Charles River) were used. Animals were 
pair-housed with the same sex on a 12:12 h light/dark cycle (lights on at 08:00). Access 
to food and water was available ad libitum throughout the experiments except during 
behavioral testing. All studies were approved by the Institutional Animal Care and Use 
Committee at Georgia State University, and performed in compliance with Ethical 
Issues of the International Association for the Study of Pain and National Institutes of 
Health. All efforts were made to reduce the number of animals used in these 
experiments and to minimize pain and suffering. 
Vaginal Cytology. Vaginal lavages were performed daily beginning 7 days prior to 
testing to confirm that all female rats were cycling normally and to record cycle stage at 
the time of testing (Loyd et al., 2007). 
Intra-vlPAG cannulae implantation and injections. Animals were anesthetized to 
a deep surgical plane with 5% isoflurane (maintained at 2–5% isoflurane throughout 
surgery; Henry Schein Animal Health) and bilateral guide cannulae (22 gauge; Plastics 
One) aimed at the vlPAG (anterior—posterior: 1.7 mm; mediolateral: ±0.6 mm; 
dorsoventral: −5.0 mm from lambda) were implanted stereotaxically and maintained as 
previously described (Loyd et al., 2008a; Eidson and Murphy, 2013a). Animals were 
allowed to recover 11-14 days post-cannula implantation before behavioral testing. 
Animals with blocked cannula were retained as no injection controls. No significant 
differences were observed between non-injected animals and those animals receiving 
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intra-PAG saline, so these groups are collapsed (data not shown). Animals with bilateral 
cannulae located outside of the vlPAG (e.g., in the aqueduct or deep mesencephalic 
nucleus) were considered “cannula misses” and were not included in any analyses. 
Behavioral Testing and data presentation. Thermal nociception was assessed 
using the paw thermal stimulator (Hargreaves et al., 1988; Wang et al., 2006; Loyd et 
al., 2008b; Eidson and Murphy, 2013a; Doyle et al., 2017). Briefly, for this test, the rat is 
placed in a clear Plexiglas box resting on an elevated glass plate maintained at 30°C. A 
radiant beam of light is positioned under the hindpaw and the time for the rat to remove 
the paw from the thermal stimulus is electronically recorded as the paw withdrawal 
latency (PWL) in seconds. A maximal PWL of 20 s was used to prevent tissue damage 
due to repeated application of the noxious thermal stimulus. Animals were acclimated to 
the testing apparatus 30-60 minutes per day for three consecutive days prior to the start 
of the experiment and on the day of testing. All behavioral testing took place between 
10:00 and 15:00 (lights on at 08:00). Temperature of the thermal stimulus was recorded 
before and after each trial to maintain consistent recordings between groups and did not 
exceed a range of 60-64°C throughout the course of the experiments. All testing was 
conducted blind with respect to group assignment. Data were normalized to the percent 
maximum possible effect (%MPE) using the following formula:  
%𝑀𝑃𝐸 =
𝑃𝑎𝑤 𝑊𝑖𝑡ℎ𝑑𝑟𝑎𝑤𝑎𝑙 𝐿𝑎𝑡𝑒𝑛𝑐𝑦
20 𝑠
 (100) 
 
Tissue analysis and data presentation of qPCR. At the end of each experiment, 
brains were removed, flash frozen, and sectioned at 300 μm with a Leica CM3050S 
cryostat and mounted on to sterile slides. One-millimeter bilateral micropunches were 
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taken from 6 levels of the vlPAG (Bregma -6.72, -7.04, -7.64, -8.0, -8.30, -8.80) and 
RNA was extracted with TRIzol (Life Technologies; 15596026) using standard 
procedures, followed by the addition of Glycoblue (Life Technologies; AM5916) for 
visualization. Concentrations of RNA (ng/µl) were calculated using a NanoDrop ND-
1000 Spectrophotometer (Version 3.8, Thermo Fisher; DE). Following RNA extraction, 
RNA was diluted to a standard concentration and converted to cDNA using an AMV 
First-Strand Synthesis Kit (Invitrogen). PCR was performed using FastStart Essential 
DNA Green MasterMix (Roche) and analyzed using a Roche LightCycler 96 and 
accompanying software (Version 1.1.0.1320, 2011 Roche Diagnostics; Switzerland). 
Primer sequences can be found in Table 1.  
qPCR data are presented as the normalized ratio of the target gene relative to 
the GAPDH control gene using ∆Cq to retain saline control groups. Data shown 
represent normalized values obtained using 2-(∆Cq). The impact of sex and treatment on 
activated microglia and cytokine mRNA levels were analyzed by two-way ANOVAs, with 
Tukey’s post-hoc analysis, using SigmaPlot. Bivariate correlations were performed for 
estrus cycle and cytokine expression using Spearman’s test. PCR data are presented 
as 2-(∆Cq) normalized means ±SEM; p≤0.05 was considered significant.  
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Table 2. Chapter 3 primer sequences for qPCR of inflammatory cytokines 
GAPDH 
Forward GAG GTG ACC GCA TCT TCT TG 
Reverse CCG ACC TTC ACC ATC TTG TC 
IL-1β 
Forward CCC TGA AGG ATG TGA TCA TTG 
Reverse GGC AAA GGG TTT CTC CAC TT 
IL-6 
Forward AAG ACC CAA GCA CCT TCT TT 
Reverse AGA CAG CAC GAG GCA TTT TT 
IL-10 
Forward TGT ACC TTA TCT ACT CCC AGG TTC TCT 
Reverse GTG TGG GTG AGG AGC ACG TA 
TNF 
Forward TGT ACC TTA TCT ACT CCC AGG TTC TCT 
Reverse GTG TGG GTG AGG AGC ACG TA 
 
 
 Experiment 1: Does the administration of M6G eliminate sex differences in 
analgesia? 
Cannula implantation and behavioral testing. To determine if M6G produces 
equipotent analgesia in males and females, thermal nociception was assessed using 
the paw thermal stimulator immediately following a single injection of M6G into the 
vlPAG. Following baseline PWL measures, animals received a single injection of M6G 
(0.2ug or 0.7ug) into the PAG (Mathes and Kanarek, 2006) and immediately placed 
back into the testing chamber. PWL was measured every 10 minutes for 120 minutes 
following injection. A separate group of animals received a single injection of morphine 
as a positive control (7 µg/0.25 µl/side; (Loyd et al., 2008a)), or saline as a negative 
control (0.25 ul/side), resulting in 4 total groups: Saline (n=9 males, 7 females), 
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Morphine (n= 8 males, 16 females), M6G Low-Dose (n=9 males, 10 females), M6G 
High Dose (n=10 males).  
To confirm action of M6G at μ opioid receptor and not TLR4, animals received a 
single injection of M6G at the effective dose (0.2 ug in females, 0.7ug in males), 
followed by a single subcutaneous injection of (-)-naloxone (3.7 mg/kg; (Wu et al., 
1997)) or (+)-naloxone (8.0 mg/kg) immediately following the PWL measurement at the 
20-min time-point. This resulted in 4 additional groups: Saline + (-)-naloxone (n= 6 
males, 4 females), M6G + (-)-naloxone (n= 7 males, 5 females), Saline + (+)-naloxone 
(n= 5 males, 5 females), and M6G + (+)-naloxone (n= 7 males, 6 females). Animals 
treated with Saline and (-)-naloxone or (+)-naloxone are not statistically different from 
Saline-only animals, therefore, these groups are pooled for analysis and presentation 
(data not shown).  
Data analysis and presentation. Paw withdrawal latency was normalized to 
%MPE and analyzed using SigmaPlot. Maximum analgesic effects of M6G and 
morphine were observed between 10-60 minutes post-injection, therefore, data are 
analyzed across the first 60 minutes. Data were analyzed by group across time using a 
two-way repeated measures ANOVA with Greenhouse-Geisser correction when 
appropriate using SigmaPlot. Area under the curve (AUC) was also calculated using 
%MPE data and analyzed using two-way ANOVAs. Tukey’s post hoc tests were used 
for all ANOVAs; values of p≤0.05 were considered statistically significant.  
Examination and presentation of immunomodulatory cytokines using qPCR. To 
determine if M6G activates microglia via TLR4, brain tissue was collected from animals 
in Experiment 1.1 for analysis of inflammatory cytokines using qPCR. 
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 Experiment 2:  Does M3G alter morphine analgesia via TLR4?  
Intra-vlPAG cannulae implantation and injections. To determine if PAG TLR4 
activation with M3G impacts morphine analgesia, animals were implanted with bilateral 
cannula aimed at the vlPAG. On the day of testing, animals received a single intra-PAG 
injection of M3G (0.075 μg/0.25 μl/side; NIDA) or saline (0.25 μl/side). Comparable 
doses have been shown to increase glial activation and cytokine expression when 
administered intrathecally (Lewis et al., 2010).  
Approximately 45 minutes following the initial injection of M3G, behavior testing 
was used to calculate morphine ED50 values using our cumulative dosing paradigm. 
Briefly, animals received an injection of morphine every 20 minutes, resulting in 
cumulative doses of 1.8, 3.2, 5.6, 8.0, 10.0, and 18 mg/kg. Control animals received 
repeated saline injections (1ml/kg; s.c). A total of four primary treatment groups were 
generated: Saline+Saline (n=5 males, 5 females), M3G+Saline (n=8 males, 7 females), 
Saline+Morphine (n=5 males, 7 females), and M3G+Morphine (n=9 males, 7 females).  
To determine if M3G activation occurs via TLR4, a separate group of animals 
receiving intra-PAG M3G also received a peripheral injection of the TLR4 antagonist 
(+)-naloxone (s.c.; 8mg/kg) immediately prior to behavioral testing. This dose was 
chosen based on previous studies demonstrating inhibition of morphine-induced TLR4 
activation of microglia within the PAG (Eidson and Murphy, 2013a). Two additional 
groups were generated to test the effects of M3G at TLR4: Saline + (+)-naloxone (n=4 
males, 4 females), and M3G + (+)-naloxone (n=8 males, 8 females). Animals treated 
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with Saline + (+)-naloxone were not statistically different from animals treated with 
Saline-only, therefore these groups are pooled (data not shown). 
Data analysis and presentation. For morphine-treated animals, half-maximal 
antinociceptive effect (ED50) and 95% confidence intervals (CI) were calculated from 
dose–response curves using Graph-Pad PRISM software. To generate curves, data 
was normalized such that each individual animal’s baseline PWL score = 0% and 20s = 
100% (Morgan et al., 2006; Eidson and Murphy, 2013a; Eidson et al., 2016). Repeated 
measures ANOVA was used to assess for significant treatment effects, with 
Bonferroni’s post hoc tests where appropriate. GraphPad PRISM does not generate 
exact p-values, therefore these values are presented as p< or >0.05; values of p≤0.05 
were considered statistically significant.  
Examination and presentation of immunomodulatory cytokines using qPCR. To 
determine of M3G sex-specifically alters glial activation via TLR4, brain tissue was 
collected from animals in Experiment 2.1 for analysis of inflammatory cytokines using 
qPCR. 
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 Results 
 Experiment 1a: M6G is more effective in females 
Exogenous M6G produces robust analgesia, and is reported to have greater 
potency than morphine presumably by acting exclusively via MOR, therefore bypassing 
the opposing effects mediated by TLR4 (Abbott and Palmour, 1988; Christrup, 1997; 
Kilpatrick and Smith, 2005)]. To test the hypothesis that M6G activation of MOR (and 
not TLR4), results in equipotent analgesia, animals received a single injection of M6G 
(0.2ug), morphine (7.0ug) or saline directly into the vlPAG.  
Across the initial 60 minutes following intra-PAG injections, a significant 
interaction was observed between group and time (F(36,306)= 5.80, p<0.001); Figure 
3.3.1a. As expected, morphine significantly increased analgesia in both males (p=0.002) 
and females (p<0.001) compared with saline controls. Morphine produced greater 
analgesia in males than in females 30-60 minutes post-injection, with males having 
significantly greater analgesia at 40-minutes post-injection (p=0.04; Figure 3.3.1b).  
Administration of M6G to females resulted in robust analgesia. Indeed, this 
response was greater than females receiving morphine alone, however, these groups 
were not statistically different (Average MPE: 69% vs 87%; p=0.07). Interestingly, M6G 
at low doses was significantly more effective in females than in males (p= 0.007). 
Although males receiving low-dose M6G had greater analgesia than saline-treated 
males, these groups were not statistically different (Average MPE: 59% vs 34%; 
p=0.08). To determine if the discrepancy in M6G analgesia between males and females 
was due to differences in drug potency, a higher dose of M6G (0.7ug) was also 
administered. Males were maximally analgesic at high doses of M6G, and did not 
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significantly differ from females receiving low-dose M6G (p=0.99) or from males 
receiving morphine (p=0.46). High-dose M6G was fatal in females, and this dose was 
discontinued following pilot studies.  
 
 Mechanisms of M6G analgesia 
Administration of (-)-naloxone significantly and completely antagonized the 
analgesic effects of M6G in both males (p<0.001) and females (p<0.001); F(15,147)=2.12, 
p=0.02, Figure 3.3.2a. Indeed, within 20 minutes of administration, PWLs were not 
significantly different from saline in males (p=0.54) or females (p=0.49). By contrast, 
administration of the TLR4 antagonist (+)-naloxone had no effect on M6G-induced 
analgesia in either males (p=0.90) or females (p=0.99); F(15,153)=2.17, p=0.018; Figure 
3.3.2b. Administration of either (-)-naloxone or (+)-naloxone had no effect on PWL 
latency alone in males (p>0.99 and p>0.99) or females (p>0.99 and p>0.99, 
respectively). Together, these results suggest that the analgesic effects of M6G are 
mediated via an action at MOR, and not TLR4.  
 
 
68 
 
Figure 3.3.1. M6G Induces Robust Analgesia in Both Sexes, but is More Potent in Females.  
a) M6G induces robust analgesia in both sexes. Low dose M6G (0.2ug) was effective in females but not 
males. b) At 40 minutes post-injection, at the time of peak morphine analgesia, significant sex differences 
were observed between morphine treated males and females. Effective doses of M6G (0.2ug in females, 
0.7ug in males) did not show significant sex differences at 40 minutes, or c) across the first 60 minutes of 
the test. Saline (n=9 males, 7 females), Morphine (n= 8 males, 16 females), M6G Low-Dose (n=9 males, 
10 females), M6G High Dose (n=10 males). 
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Figure 3.3.2. Receptor Mechanisms Underlying M6G Analgesia.  
a) Inhibition of MOR with (-)-naloxone (s.c.) results in complete blockade of M6G analgesia, while b) 
inhibition of TLR4 with (+)-naloxone (s.c.) has no effect on PWL. Saline + (-)-naloxone (n= 6 males, 4 
females), M6G + (-)-naloxone (n= 7 males, 5 females), Saline + (+)-naloxone (n= 5 males, 5 females), 
and M6G + (+)-naloxone (n= 7 males, 6 females).  
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  Experiment 1b – M6G does not alter cytokine profiles 
M6G has immunomodulatory effects on peripheral immune function, resulting in 
reduced cytokine production, decreased B cell and lymphocyte proliferation, and 
reduced natural killer cell activity (Thomas et al., 1995; Carrigan and Lysle, 2001). 
However, it is unknown if M6G is capable of altering central cytokine concentrations. 
Therefore, qPCR was used to determine cytokine expression in the vlPAG of morphine- 
and M6G-treated males and females from experiment 1a; Figure 3.3.3.  
Significant treatment effects were found for IL-6 (F(4,70) =5.86, p<0.001) and IL-10 
(F(4,72) =2.97, p=0.026), while significant interactions were found for IL-1β (F(4,66) =6.58, 
p<0.001), and TNF (F(4,70) =3.28, p=0.017). No significant main effects of sex were 
observed. In females, IL-1β expression was significantly increased with M6G relative to 
Saline (p<0.001), Morphine (p=0.002), and M6G + (+)-naloxone (p=0.002), Figure 
3.3.3a. Morphine significantly increased IL-1β expression in males relative to saline 
(p=0.002). Morphine also increased expression of IL-6 and TNF in females relative to 
saline (p=0.004 and p=0.005, respectively). Intra-PAG M6G did not have a significant 
impact on cytokine expression of IL-6, TNF, or IL-10 within the PAG for either males or 
females. 
Treatment with peripheral (-)-naloxone or (+)-naloxone following M6G 
administration had inconsistent effects on cytokine expression. Females receiving 
M6G+ (-)-naloxone showed significantly increased TNF relative to their male 
counterparts (p=0.009), as well as females treated with M6G alone (p=0.02), Figure 
3.3.3c. Females receiving M6G + (+)-naloxone also showed significantly increased TNF 
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relative to their male counterparts (p=0.003), as well as increased IL-10 expression 
relative to females treated with M6G alone (p=0.04), Figure 3.3.3d. 
 
 
Figure 3.3.3. M6G Immunomodulation in the PAG.  
a) IL-1β was significantly increased in M6G treated females relative to Saline and Morphine-treated 
females, M6G + (+)-naloxone females, and M6G males. b) IL-6 expression was significantly increased in 
morphine-treated females relative to saline females. C) TNF expression is significantly greater in 
Morphine females relative to Saline controls. TNF was also expressed significantly more in M6G + (-)-
naloxone females relative to females treated with M6G only, as well as M6G + (-)-naloxone males. Sex 
differences were observed in the M6G + (+)-naloxone group. d) IL-10 expression was significantly 
increased in M6G + (+)-naloxone females relative to females treated with M6G alone. Saline (n=14 
males, 12-13 females), Morphine (n= 4-6 males, 5-7 females), M6G Low-Dose (n=5 females), M6G High 
Dose (n=4-5 males), M6G+(-)-naloxone (n=5-6 males, 5-6 females), and M6G+(+)-naloxone (n=5 males, 
6-7 females).  
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 Experiment 2a: M3G attenuates morphine analgesia in males only  
Previous studies reported that the morphine metabolite M3G, binds to TLR4, 
producing allodynia and hyperalgesia, actively opposing the analgesic effects of 
morphine and M6G (Yaksh et al., 1986; Smith et al., 1990; Ekblom et al., 1993; Bartlett 
et al., 1994; Smith and Smith, 1995; Angst and Clark, 2006). To determine if M3G 
induced hyperalgesia or morphine opposition in a sex-specific manner, a single injection 
of M3G (0.075 ug) or saline was administered into the vlPAG of male and female rats 
45 min. prior to receiving cumulative injections of morphine or saline. 
Repeated measures ANOVA of morphine-treated groups shows significant effect 
of treatment across time; F(3,27)= 6.54, p=0.004; Figure 3.3.4. Consistent with our 
previous studies, morphine ED50 was significantly greater in females than males (ED50= 
7.81 and 5.00 respectively), indicating greater morphine efficacy in males (p<0.05). 
Interestingly, pre-treatment with M3G significantly attenuated morphine analgesia in 
males only (p<0.01), completely abolishing the sex difference in morphine response 
(ED50= 10.28 and 8.82 in males and females, respectively p>0.05); Figure 3.3.4a.  
We observed a significant effect of treatment, regardless of time in saline-treated 
groups; F(7,245)=9.00, p<0.001; Figure 3.3.4b. No sex differences in baseline responses 
to the thermal stimulus were noted in our saline control groups (p=0.64). In addition, 
M3G alone did not significantly alter response latencies from saline control within male 
(p=0.99) or female (p=0.94) groups. M3G marginally increased PWL in males (AUC 
61.7s vs 68.2s) and decreased it in females (AUC 57.9s vs 55.5s), such that a 
significant sex difference was observed in M3G-treated animals (p=0.003).  
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To determine if M3G was acting in a TLR4-dependent manner, the TLR4-specific 
antagonist (+)-naloxone was administered immediately following M3G. Male and female 
groups receiving only (+)-naloxone were significantly different from one another 
(p=0.04). Interestingly, (+)-naloxone had no effect on M3G-treated males (p=1.0) or 
females (p=0.67) compared with M3G alone, and no sex differences were observed 
between males and females treated with M3G + (+)-naloxone (p=0.17); Figure 3.3.4b.  
Together, these data demonstrate that increased concentrations of M3G in the 
PAG are sufficient to attenuate morphine antinociception in males. However, no 
statistically significant effects of M3G alone or in combination with (+)-naloxone were 
observed. 
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Figure 3.3.4. M3G Attenuates Morphine Analgesia in Male, but not Female, Rats.  
a) Intra-PAG administration of M3G significantly attenuates morphine analgesia in males, but not females; 
Saline+Morphine (n=5 males, 7 females), and M3G+Morphine (n=9 males, 7 females). b) M3G alone was 
not sufficient to induce observable changes in PWL, and was not changed with (+)-naloxone; 
Saline+Saline (n=5 males, 5 females), M3G+Saline (n=8 males, 7 females), Saline+Naloxone (n=4 
males, 4 females), and M3G+Naloxone (n=8 males, 8 females). 
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 Experiment 2b: M3G alters cytokine profiles 
M3G is known to induce pro-inflammatory responses that oppose the analgesic 
effects of morphine (Lewis et al., 2010; Due et al., 2012; Grace et al., 2014; Xie et al., 
2017). To determine if M3G induced comparable levels of neuroinflammation in males 
and females in vivo, PAG punches were collected in experiment 2a following behavior 
testing, and cytokines were measured using qPCR.  
A significant interaction effect was observed for IL-1β (F(4,61) =3.01, p=0.026). 
Females treated with M3G+Morphine had significantly higher levels of IL-1β expression 
than females receiving morphine alone (p=0.009), or males receiving M3G+Morphine 
(p=0.04); Figure 3.3.5a. A main effect of treatment was observed for IL-6 (F(4,63) =5.23, 
p<0.001). Regardless of sex, M3G+Morphine treated animals had greater IL-6 
expression relative to groups treated with morphine alone (p=0.019); Figure 3.3.5b. 
Main effects of both sex and treatment were observed for TNF (F(4,65) =10.24, p=0.002 
and F(1,65) =4.99, p=0.002, respectively), however no interaction effects were observed. 
Females treated with M3G alone had significantly more TNF expression than females 
treated with morphine (p=0.005), or M3G-treated males (p=0.02); Figure 3.3.5c. No 
significant main effects or interactions were detected for IL-10; Figure 3.3.5d. Indeed, 
IL-10 levels were remarkably stable regardless of treatment or sex. Surprisingly, (+)-
naloxone administration did not block M3G-induced increases in IL-1β, IL-6, or TNF.  
Overall, neither subcutaneous morphine nor intra-PAG M3G administration were 
sufficient to alter cytokine expression in the vlPAG relative to Saline groups. However, 
the combination of M3G+Morphine significantly increased IL-1β in females and IL-6 in 
both sexes. Although M3G has been previously shown to augment cytokine levels in a 
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TLR4-dependent manner in vitro, co-administration of the TLR4 antagonist (+)-naloxone 
did not significantly impact M3G-induced increases in IL-1β, IL-6, and TNF. 
 
 
Figure 3.3.5. M3G Immunomodulation in the PAG.  
a) IL-1β and b) IL-6 expression significantly increased in M3G+Morphine treated females relative to 
morphine-only controls. Sex differences in IL-1β expression were observed between males and females 
treated with M3G + (+)-naloxone. c) TNF expression significantly increased in M3G females relative to 
morphine females as well as M3G males. Significant sex differences were observed in TNF expression 
between males and females treated with M3G + (+)-naloxone. d) No changes in IL-10 expression were 
observed between any treatment groups. Saline (n=9 males, 8 females), M3G+Saline (n=5-7 males, 5-6 
females), Saline+Morphine (n=5 males, 6-7 females), M3G+Morphine (n=6-7 males, 6-7 females), and 
M3G+Naloxone (n=5-6 males, 5-6 females). 
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 Discussion 
The present study examined both the behavioral and immunomodulatory effects 
of the morphine metabolites, M3G and M6G. Intra-PAG administration of M6G results in 
significantly greater analgesia in females than in males. Importantly, M6G resulted in 
near maximal analgesia in females, a 26% increase from maximal morphine analgesia.  
In both males and females, M6G analgesia was reversed with (-)-naloxone but 
was unchanged with (+)-naloxone, consistent with previous studies showing that M6G 
acts at MOR, but not glial TLR4 (Abbott and Palmour, 1988; Wittwer and Kern, 2006; 
Hutchinson et al., 2010). M3G administration resulted in a significant rightward shift in 
the morphine dose response curve, in males only. In contrast, pretreatment with M3G in 
females did not alter the response to morphine, suggesting a ceiling effect of M3G. 
Despite the large and significant shifts in pain sensitivity observed following M6G 
administration in males and females, M6G did not reliably alter vlPAG proinflammatory 
cytokine concentrations, and were also not consistently changed with either (-)-
naloxone or (+)-naloxone. In contrast, concentrations of pro-inflammatory molecules in 
females treated with M3G alone or in combination with morphine were significantly 
increased, although these effects were not reversible with (+)-naloxone in either sex. 
Together, these data indicate that M3G may contribute to the attenuation of morphine 
analgesia observed in females, as administration of M6G, but not M3G and/or morphine 
results in significantly greater analgesia relative to males. These studies suggest that 
the immunomodulatory effects of morphine and its metabolites result in sex-dependent 
effects on pain modulation, and have far-reaching implications for the use of opioids to 
treat pain in women.  
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 Sex differences in pharmacokinetics 
Previous dogma held that there were no sex differences in morphine metabolism, 
likely due to a history of conflicting HPLC results in human studies showing both the 
presence (Murthy et al., 2002) and absence (Sarton et al., 2000; Romberg et al., 2004) 
of sex differences in M3G or M6G concentrations following morphine treatment. 
However, pre-clinical studies in rats have consistently reported significant sex 
differences in metabolite concentrations using HPLC (South et al., 2001; Baker and 
Ratka, 2002; South et al., 2009), with a single exception, see (Cicero et al., 1997). To 
date, few studies have examined the effect of endogenous morphine metabolites on 
pain modulation—and to our knowledge, the present experiments are the first to 
demonstrate sex-specific causal relationships.  
Results from pharmacokinetic studies also support sex-specific differences in 
morphine metabolism. In humans, morphine is metabolized by isozymes in the uridine 
5'-diphospho-glucuronosyltransferase (UGT) 1 and 2 subfamilies, almost all 
preferentially synthesizing M3G over M6G (~45-55% and 15% of metabolized product, 
respectively; (De Gregori et al., 2012)). Importantly, sex differences in the expression of 
UGT1 and 2 subclasses of enzymes have been reported in humans (Gallagher et al., 
2010) and rats (Iwano et al., 2012). Further, the enzymes metabolize, and are directly 
influenced by, steroid hormones (Strasser et al., 1997). In rats, gonadectomy 
significantly decreases the M3G:morphine ratio in females only, suggesting the 
involvement of steroid hormones in mediating sex differences in morphine metabolism 
(Baker and Ratka, 2002). To date, no studies have examined the effects of sex or 
gonadal hormones on the expression of these isozymes in brain tissue.  
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 Immunomodulatory effects of morphine metabolites 
M6G is a known immunomodulator, with predominantly anti-inflammatory effects 
(Thomas et al., 1995; Carrigan and Lysle, 2001), although the exact mechanism 
through which M6G exerts its effects on immune function is uncertain. Here, M6G 
increased expression of IL-1β, but did not change expression of IL-6, TNF, and IL-10 
relative to saline controls. Antinociceptive and immunomodulatory effects of M6G have 
been classically attributed to neuronal MOR (Carrigan and Lysle, 2001; Lysle and 
Carrigan, 2001); however, no studies have investigated the possibility of M6G exerting 
its effects via MOR on CNS glial cells, which may account for the discrepancies in 
immune modulation between previous and present studies (Gessi et al., 2016). 
Inflammatory mechanisms of M3G have been established, as M3G significantly 
increases pro-inflammatory IL-1β mRNA in BV-2 microglia cultures (Lewis et al., 2010). 
TLR4 activation by M3G is modest relative to TLR4’s natural agonist lipopolysaccharide 
(LPS; (Hutchinson et al., 2010)), and may not induce robust increases cytokine 
concentrations in vivo (Lewis et al., 2010; Xie et al., 2017). In the present study, we 
report that M3G, administered in combination with morphine, results in increased 
expression of IL-1β in females and IL-6 in both sexes relative to saline-treated controls. 
However, M3G alone was not sufficient to alter cytokine expression in the PAG, 
suggesting that, in vivo, central M3G does not produce measurable immune activation 
relative to peripheral LPS, which has robust sex-specific effects on cytokine expression 
in the PAG (Doyle et al., 2017).  
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Overall, patterns of cytokine expression observed following M3G or M6G 
treatment were equivocal, and not consistently reversed with (+)-naloxone or (-)-
naloxone. Similar inconsistencies have been reported, suggesting a complicated role for 
morphine metabolites and their relative contributions to immune modulation following 
morphine (Thomas et al., 1995; Hashiguchi et al., 2005). Estrus cycle was monitored in 
the present experiments, however, stage of estrus did not correlate with the observed 
variability in qPCR results. A number of other factors may play a role; for example, route 
of drug administration [intracerebroventricular vs. subcutaneous (Hashiguchi et al., 
1998)], and duration [acute vs. chronic administration; (Eckhardt et al., 2000)] have 
been shown to alter metabolite-induced, immune-related activity. Immune modulation by 
M3G and M6G remains vastly understudied, and further experiments comparing brain 
cytokine concentrations using various doses, time-points, and routes of administration 
will be useful to understand how M3G and M6G each contribute to immune modulation. 
 Behavioral effects of morphine-6-glucuronide 
In the present study, we hypothesized that in the absence of immune activation 
by M3G or morphine, M6G would produce equipotent analgesia in males and females. 
This is supported by a study in healthy human subjects demonstrating no sex 
differences in analgesic responses to M6G between males and females (Romberg et 
al., 2004). Surprisingly, we found that exogenous administration of M6G produces 
significantly greater analgesia in females than in males. Along with our previous data, 
this finding provides a new converging line of evidence to support our hypothesis that 
TLR4 is a primary contributor to sex differences in morphine action. It also initiates 
exciting and important questions regarding the mechanisms of opioid analgesia; 
81 
specifically, why and how does M6G produce robust analgesia in females compared 
with many other opioids that produce more potent analgesia in males (Barrett et al., 
2002; Terner et al., 2003; Stoffel et al., 2005; Peckham and Traynor, 2006; Bai et al., 
2015)? 
One possible explanation for the reversal of sex differences observed with M6G, 
is that M6G is able to better utilize MOR than morphine. The PAG sends dense 
projections to the rostral ventromedial medulla (RVM), which together with descending 
projections to the spinal cord dorsal horn, constitute the endogenous descending 
analgesia circuit. Previous analtomical studies in our lab have reported that the density 
of PAG-RVM output neurons is significantly greter in females frompared with males. 
However, despite this difference in the number of projection neruons, the percent of 
PAG-RVM neurons activated by morphine is significantly greater in males (20% vs 
50%) (Loyd and Murphy, 2006; Loyd et al., 2008b). Based on the resuls of the present 
study, we would predict that M6G activates a greater proportion of PAG-RVM neurons 
than morphine in females than in males, resulting in improved analgesia. Further 
investigation of the binding properties of M6G in males and females is clearly 
warranted.  
 Behavioral effects of morphine-3-glucuronide 
Interestingly, the present study shows that injection of M3G into the vlPAG prior 
to morphine administration causes a significant attenuation of morphine analgesia in 
males only. It has been previously reported that female rats metabolize approximately 
2-3 times more M3G than their male counterparts following a single systemic injection of 
morphine (Baker and Ratka, 2002; South et al., 2009). M3G levels are significantly 
82 
higher in females following morphine; therefore, we suspect that the lack of behavioral 
effect observed in females is due to saturation of M3G at TLR4 (i.e., a ceiling effect of 
M3G). This interpretation is consistent with our hypothesis that increased M3G reduces 
morphine’s effects, and may contribute to sexually dimorphic responses to morphine.  
We did not observe changes in PWL with administration of M3G alone. This is 
likely due to discrepancies in testing procedures, as previous studies examining M3G 
adjusted baseline PWL to ~10s in order to observe hyperalgesia (Lewis et al., 2010). 
However, the present experiments used a lower baseline threshold (approx. 4-7s; 
consistent with our previous studies (Loyd et al., 2008a; Eidson and Murphy, 2013a)) to 
accommodate increases in PWL as a result of morphine administration. This may have 
created a behavioral floor effect for animals treated with M3G alone, and decreases in 
PWL due to hyperalgesia may not be statistically observable at the current threshold. 
The sex-specific effects we observe here with M3G have broad implications that 
apply to other opioids that create 3-glucuronide metabolites. Glucuronidation at the 3-
site of the substrate molecule is associated with glial activation and neuronal excitability; 
for example, morphine-3-glucuronide (Lewis et al., 2010) and estradiol-3-glucuronide 
(Lewis et al., 2015), activate glial cells in a TLR4-dependent manner, increasing the 
release of pro-inflammatory mediators, ultimately resulting in increased neuronal 
excitation. Hydromorphone-3-glucuronide (Smith, 2000) and normorphine-3-glucuronide 
(Smith et al., 1997) also have been shown to increase neuronal excitability, likely 
through the same mechanisms. Interestingly, exogenous opioids with the greatest sex 
difference in ED50 in rats (oxymorphone, hydromorphone, and morphine (Peckham and 
Traynor, 2006)) all produce 3-glucuronide metabolites by Phase II metabolism via 
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UGTs. In contrast, drugs producing comparable ED50’s in males and females (codeine, 
oxycodone, fentanyl) undergo Phase I metabolism by cytochrome P450 (CYP) 
enzymes, and therefore do not produce 3-glucuronide metabolites on their first pass 
(Holtman and Wala, 2006; Chan et al., 2008; Smith, 2009). More research is needed to 
understand how metabolism and elimination of these drugs may differ in males and 
females, and how 3-glucuronide metabolites impact analgesia. 
Together, these data demonstrate an important proof of principle: that in the 
absence of TLR4 signaling, opioid analgesia is equally effective—if not more effective—
in females than in males. Historically, M6G has not been used for the treatment of 
clinical pain in humans. This is perhaps due to its “low and slow” blood brain barrier 
permeability, high variability in the doses of M6G required to induce analgesia 
(depending on the type of pain and method of administration), and tendency to 
accumulate in plasma in patients with impaired renal function [see (Lotsch and 
Geisslinger, 2001; Kilpatrick and Smith, 2005) for review]. However, clinical trials of 
M6G demonstrate comparable analgesia to morphine at appropriate doses, while 
reducing the negative side effects typically associated with morphine, such as nausea 
and sedation, in both men and women (Cann et al., 2002; Romberg et al., 2004; Hanna 
et al., 2005; Dahan et al., 2008). Clearly, further research is required to address the 
relevance of treatment with M6G, as these studies may provide insight into improved 
treatment strategies for pain management in females.  
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4 GENERAL DISCUSSION 
 Summary: Sex differences in vlPAG glial activity significantly contribute to 
morphine efficacy via TLR4 
Opioids are the most commonly used prescription medications for severe pain, with 
approximately 1 in 5 Americans prescribed opioids each year (Daubresse et al., 2013). 
Women are more likely than men to suffer from chronic inflammatory conditions, and to 
be prescribed opioid drugs for the treatment of pain (Frenk et al., 2015). Unfortunately, 
women experience increased negative side effects of opiate use (Fillingim et al., 2009), 
and decreased analgesic efficacy relative to men (Cepeda and Carr, 2003). Rodent 
studies from our lab and others demonstrate that females require approximately two 
times as much morphine to achieve analgesia comparable to males (Craft et al., 1999; 
Ji et al., 2006; Wang et al., 2006; Loyd et al., 2008b).  
Many mechanisms have been identified as contributing to the dimorphic effects of 
morphine, including reproductive hormones (Craft, 2007), GABA, glutamate and 
melanocortin-1 signaling (Mao, 1999; Tonsfeldt et al., 2016), and MOR density and tone 
(Loyd and Murphy, 2014) [see Table 3]. The fact that so many seemingly competitive 
theories exist to account for the dimorphic response to morphine implies a parallel 
and/or upstream mediator of these effects. Given the inverse relationship between glial 
activation and analgesia [see Table 4], and the known contribution of glial TLR4 to 
modulate morphine analgesia in male rats (Eidson and Murphy, 2013a) we 
hypothesized that sex differences in innate immune function are a likely precursor 
and/or a significant contributor to the sexually dimorphic actions of morphine. 
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The data presented in Chapters 2 and 3 demonstrate that innate immune glial cells, 
via TLR4 signaling, contribute to the sexually dimorphic effects of morphine in the rat. 
Specifically, sex differences in microglial activation were found in the PAG, as females 
have a significantly larger proportion of microglia in the PAG with an “activated” 
morphology, both at baseline and following immune challenge with LPS. Although acute 
morphine treatment is not sufficient to alter the morphological state of microglia in the 
PAG, the percentage of endogenously activated glia in this region significantly 
correlates with morphine ED50. This indicates that the baseline level of microglia 
activation in the PAG can predict the dose of morphine required to elicit analgesia; 
specifically, as the proportion of activated glia in the PAG increases, morphine 
analgesia decreases. Importantly, we demonstrate that PAG TLR4 is both sufficient and 
necessary to drive sex differences in morphine response. Activation of PAG glia with 
LPS prior to morphine administration reduces male analgesia to “female-typical” levels, 
and reduces or abolishes analgesia in a subset of females. On the other hand, inhibition 
of PAG TLR4 with (+)-naloxone increases morphine analgesia in females, abolishing 
observed sex differences in morphine response.  
Further, we demonstrate that morphine metabolites have sex specific effects on 
analgesia that may contribute to the sexually dimorphic response to morphine, as 
increased concentrations of M3G in the PAG prior to morphine administration decrease 
male analgesia to “female-typical” levels, similar to LPS, abolishing sex differences in 
analgesia. With administration of M6G, female analgesia not only matches, but 
surpasses male analgesia—suggesting that in the absence of TLR4-induced signaling, 
sex differences in response to opioids are reversed.  
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 Current hypotheses underlying sex differences in morphine analgesia are 
linked with glial activity 
Together, the present body of work strongly implicates PAG TLR4 in driving the 
sex differences in morphine analgesia, and suggests that opioid efficacy is dependent 
upon glial activation in the PAG. Indeed, previous hypotheses that have been proposed 
to underlie sex differences in morphine analgesia are all directly linked with glial activity: 
 
 Estradiol 
Studies employing a variety of techniques and pain modalities have assessed the 
role of steroid hormones, and in particular estradiol, in modulating pain and opiate 
analgesia. In terms of basal sensitivity, the majority of preclinical studies report no 
differences in somatosensory thresholds across the estrus cycle, although pro- and anti-
nociceptive effects of estradiol have also been reported (Craft, 2007; Craft et al., 2008). 
In terms of opiate analgesia, several general claims can be made regarding the role of 
hormones in preclinical studies using rodents [for review, see (Craft et al., 2004)]: (1) 
morphine is most efficacious in intact males and gonadectomized males supplemented 
with testosterone; (2) morphine is least efficacious in females supplemented with 
estradiol; and (3) in normally cycling females, morphine responses are decreased in 
proestrus and estrus stages, when circulating hormones peak, relative to diestrus. 
Together, this body of literature suggests that female hormones, specifically estradiol, 
decreases the analgesic potency of morphine.  
Estradiol is a contributing factor in sex differences in immune function. CNS 
immune cells, specifically astrocytes, express the enzymes 5a-reductase and 3a-
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hydroxysteroid dehydrogenase) and are implicated in both progesterone and 
testosterone metabolism (Garcia-Segura and Melcangi, 2006). Glial cells do not 
express aromatase for the conversion of testosterone into estradiol under normal 
conditions (Garcia-Segura and Melcangi, 2006); however, astrocytes and microglia 
possess steroid hormone receptors, including estrogen receptor alpha (ERα), making 
them susceptible to changes in estradiol across the estrus/menstrual cycle (Sierra et al., 
2008).  
Estradiol has a well-documented biphasic effect on immune function in both 
preclinical and clinical studies (Whitacre et al., 1999; Nilsson, 2007; Straub, 2007), and 
its pro- or anti-inflammatory effects are dependent upon dose, time, and method of 
testing (in vitro vs. in vivo).  For example, high levels of estradiol (typical of pregnancy) 
decrease proinflammatory cytokine production and attenuate inflammatory responses to 
LPS (Vegeto et al., 2003; Dimayuga et al., 2005; Lewis et al., 2008). In contrast, low 
doses of estradiol, comparable to normal circulating levels, increase peripheral 
concentrations of proinflammatory cytokines (Correale et al., 1998). Removal of 
endogenous estrogens decreases cytokine production and cell-surface expression of 
TLR4 (Rettew et al., 2009). Estradiol also influences cytokine release in a time-
dependent fashion, as chronic but not acute estradiol administration increases TLR4-
mediated pro-inflammatory responses in immune cells of females compared with males 
(Soucy et al., 2005; Calippe et al., 2008; Calippe et al., 2010), and potentiates LPS-
evoked TLR4 immune responses in vitro (Loram et al., 2012). Estradiol effects may also 
be dependent upon the setting, as in vitro administration is often anti-inflammatory 
(Drew and Chavis, 2000), but estradiol administered in vivo results in pro-inflammatory 
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responses (Soucy et al., 2005; Calippe et al., 2008; Rettew et al., 2009; Loram et al., 
2012). Overall, these data suggest that 1) glial cells are responsive to gonadal 
hormones, and 2) low-dose, chronic estradiol may create a more pro-inflammatory 
environment in vivo.  
These conclusions are consistent with the present studies, as increased glial 
activation was observed in intact females in the PAG at baseline, suggesting that glial 
cells are innately more activated in females than in males. In addition, LPS immune 
challenge had a greater effect on females, increasing pro-inflammatory IL-1β, ‘activated’ 
microglial morphological subtypes, and completely abolishing morphine analgesia in a 
subset of females. To examine the system in its most physiologically relevant state, 
estrus cycle was monitored but not controlled throughout our experiments. Estrus cycle 
did not correlate with measures of glial activation in the present data, reinforcing the 
notion that the interaction between estradiol and immune function is context dependent. 
Future studies examining gonadectomized vs. intact animals may elucidate the role of 
estradiol on TLR4 in the observed effects on morphine analgesia.  
 
 GABA and glutamate signaling 
The antinociceptive effects of opiates are mediated, in part, through removal of 
GABAA-mediated inhibition on excitatory glutamatergic vlPAG neurons that project to 
the RVM and spinal cord [for review, see (Lau and Vaughan, 2014)]. Blocking GABAA 
receptor signaling, or administration of μ opioid receptor agonists, hyperpolarizes 
GABAergic interneurons to decrease (or disinhibit) GABA signaling and facilitate opioid 
analgesia (Vaughan et al., 1997). Dimorphic GABAergic and glutamatergic signaling 
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within the PAG and RVM have been identified as contributing factors to sex differences 
in opiate analgesia. GABA has been shown to influence the antinociceptive effects of 
morphine in a sex-dependent manner. Consistent with the dimorphic effects observed 
following intra-PAG morphine (Krzanowska and Bodnar, 1999; Loyd et al., 2008b), intra-
PAG administration of the GABA antagonist bicuculline produces greater analgesia in 
male rats (Bobeck et al., 2009). Further, chronic peripheral inflammatory pain decreases 
tonic GABAA-mediated currents and increases the efficacy of systemic morphine in 
females, an effect reversed by potentiation of GABAA receptor currents (Tonsfeldt et al., 
2016).  
Glutamatergic NMDA receptors have also been implicated in the sexually 
dimorphic response to opioids. In rats, NMDA antagonism increases morphine 
analgesia in both males and females; however, this effect is highly variable and is 
dependent upon the drug, dose, and nociceptive test being used (Craft and Lee, 2005; 
Holtman and Wala, 2006). In male mice, blockade of NMDA receptor signaling via 
systemic antagonist administration results in a complete attenuation in both the 
analgesic and hyperalgesic responses to high (but not low) doses of morphine [for 
review see (Mao, 1999)]. In contrast, NMDA receptor blockade results in a partial 
reduction, or has no effect on, morphine analgesia in female mice (Lipa and Kavaliers, 
1990; Nemmani et al., 2004; Waxman et al., 2010). These data suggest that NMDA 
receptor signaling is necessary to facilitate morphine antinociception in male, but not 
female mice. Using quantitative trait locus mapping in male and female mice, the 
melanocortin-1 receptor (MC1R) gene was identified as a potential ‘female counterpart’ 
to NMDA. Genetic knockout of the Mc1r gene, or pharmacological antagonism of 
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functional MC1R, produces increased μ-opioid receptor mediated analgesia and 
decreased μ-opioid hyperalgesia in females, but is without effect in males (Mogil et al., 
2003; Juni et al., 2010; Arout et al., 2015). These findings, together, suggest that NMDA 
and GABAA receptor signaling may be inherently different in males and females, and 
contribute to the dimorphic effects of morphine. 
Sex differences in glial activation likely contribute to the observed differences in 
NMDA and GABA signaling [for review see (Ji et al., 2013)]. Morphine-induced 
activation of microglia and astrocytes induces pro-inflammatory cytokine release, which 
rapidly upregulates the expression of neuronal NMDA (Wei et al., 2008; Olmos and 
Llado, 2014), and decreases cell surface expression of GABAA receptors in vitro 
(Ogoshi et al., 2005; Stellwagen et al., 2005; Tilleux and Hermans, 2007; Yan et al., 
2014). Morphine-induced TNF release has also been shown to site specifically 
downregulate glial GLAST and GLT-1 glutamate transporter expression in the vlPAG 
(Eidson et al., 2016), leading to increased glutamate in the synapse, and increased 
neuronal excitation (Mao et al., 2002). Conversely, inhibition of glial activation within the 
RVM attenuates the enhanced neuronal NMDA signaling normally observed following 
nerve-injury (Wei et al., 2008). Interestingly, several NMDA antagonists that reportedly 
potentiate morphine analgesia (including MK-801 and ketamine) (Johnston and 
Westbrook, 2005) also block microglia activation, both in vivo and in vitro (Ma et al., 
2002; Thomas and Kuhn, 2005; Murugan et al., 2011).  
The sexually dimorphic response of glia to perturbation models (Drew and 
Chavis, 2000; Aulock et al., 2006; Calippe et al., 2010; Loram et al., 2012; Engler et al., 
2016), in combination with the present studies, supports the possibility of downstream 
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sex differences in glutamate and GABA signaling that ultimately contribute to sex 
differences in opioid analgesia. Previous studies in our lab indicate that chronic 
morphine is capable of altering glutamate transporters within the PAG, however these 
studies were conducted exclusively in males (Eidson et al., 2016). Similarly, the 
experiments described above demonstrating a link between glial activation and 
glutamate/GABA signaling, when performed in vivo, were also conducted only in males 
(Wei et al., 2008; Yan et al., 2014). Thus, a clear relation between glial activation and 
glutamate/GABA signaling has never been investigated in females and additional 
studies are clearly warranted. 
 
 Opioids and opioid receptors 
Sex differences in opioidergic signaling have also been reported (Zubieta et al., 
2002; Peckham et al., 2005; Loyd and Murphy, 2006; Bernal et al., 2007; Loyd et al., 
2008b; Loyd et al., 2008a). Specifically, we have previously demonstrated that male rats 
have significantly higher levels of MOR protein and radioligand binding in the vlPAG, 
and respond more robustly to morphine, than females (Zubieta et al., 2002; Loyd and 
Murphy, 2006; Loyd et al., 2008a; Loyd and Murphy, 2009). Indeed, MOR levels are 
40% lower in proestrus females compared with males; this corresponds to the stage of 
estrus when intra-PAG morphine is least effective in modulating pain (Loyd et al., 
2008a). Further, selective ablation of vlPAG MOR-expressing neurons significantly 
attenuates the response to morphine in males but not females, indicating that the 
density of PAG MOR expression is significantly correlated with the degree of opioid 
analgesia in male, but not female, rats (Loyd et al., 2008a).  
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Given that the opioid system is inextricably linked with immune function, it is 
highly likely that microglia play a role in the development of sex differences in MOR 
expression and signaling. Opioid receptors and their endogenous ligands communicate 
bidirectionally with immune cells of the CNS, and all three opioid receptor subtypes (mu, 
kappa, and delta) have been localized on immune cells, including T-cells, B-cells, 
lymphocytes and macrophages [for review, see (Bidlack et al., 2006)]. Application of the 
endogenous opioid met-enkephalin increases LPS-induced release of proinflammatory 
IL-1β in primary brain cultures (Kowalski et al., 2002), while application of 
proinflammatory IL-1β or TNFα increases pro-enkephalin expression in astrocytes 
(Spruce et al., 1990). Similarly, the potent endogenous MOR agonists endomorphin 1 
and 2 (EM1 and EM2) are expressed in immune cells and upregulated in response to 
peripheral inflammation (Jessop et al., 2000; Mousa et al., 2002). EM2 has been shown 
to modulate cytokine production (decreased TNFα and IL-10, increased IL-1β; (Azuma 
and Ohura, 2002), although the mechanism whereby EM2 and immune function 
contribute to the sexually dimorphic effects observed following endomorphin 
administration is not clear  (Liu and Gintzler, 2013; Kumar et al., 2015b; Kumar et al., 
2015a). 
Neuronal MOR tone is also modified by increased glial activity in males such that 
the release of proinflammatory cytokines upregulates MOR expression both in vivo (Ji et 
al., 1995; Ruzicka and Akil, 1997; Mousa, 2003; Puehler et al., 2004) and in vitro 
(Ruzicka et al., 1996; Borner et al., 2004). In females however, glial activation does not 
similarly upregulate MOR expression (Zhang et al., 2014), suggesting that analgesia  
may be buffered by an increase in MOR following immune challenge in males but not 
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females. Together, these data support a bidirectional link between MOR and glia, 
suggesting that increased glial cells activity may influence MOR activity, contributing to 
the attenuated response to morphine observed in females. Our present data indicate 
increased activity of glial cells within the PAG, which may influence MOR tone and 
contribute to the dimorphic expression of MOR observed in our earlier studies (Loyd et 
al., 2008a).  
Our novel studies examining M6G demonstrate that in the absence of TLR4 
signaling, MOR-induced analgesia is more effective in females than in males. The 
reversal of sex differences in analgesic response with M6G suggests unique and sex-
specific binding properties not shared by other MOR agonists (e.g. longer time at the 
receptor, or increased affinity in females). M6G, though more efficacious at MOR than 
morphine, has decreased affinity at the MOR receptor [see (Kilpatrick and Smith, 2005) 
for review], however, the binding properties of M6G have never been compared directly 
between males and females. Future studies examining MOR activation and binding by 
M6G are necessary, and may reveal novel pharmacokinetic mechanisms that can be 
applied to the development of new therapeutic drugs that improve analgesia in females 
relative to current opioid treatments.  
 
 Alternative pain treatments further suggest a role for glia 
The data presented in this dissertation suggest a clear relation between 
analgesic efficacy and immune activity in females. Although a formal examination of our 
hypothesis has not been performed in the clinic, human studies have been inadvertently 
investigating sex differences in immune-derived pain and analgesia for quite some time. 
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The use of non-steroidal anti-inflammatory drugs (NSAIDs) as an alternative treatment 
in women is perhaps the most clinically relevant example of this conclusion. 
NSAIDs inhibit the enzyme cyclooxygenase (COX), which is responsible for 
production of inflammatory prostanoids. COX exists in two isoforms: COX-1, which is 
constitutively expressed in most cells, and COX-2 which is expressed more selectively 
in immune macrophages and is upregulated in response to inflammation (Hawkey, 
2001; Bertolini et al., 2002). Importantly, COX-2 is a pro-inflammatory product of TLR4-
mediated immune signaling (Cao et al., 1997; Zhang et al., 2008; Czapski et al., 2010; 
Tse et al., 2014; Gaikwad and Agrawal-Rajput, 2015). NSAIDs are commonly used in a 
clinical setting to reduce inflammation, and also as an opioid adjuvant (a non-opioid 
drug used to improve the efficacy of opioids, and reduce the negative side effects 
associated with opioid consumption) in both men and women (Elia et al., 2005). 
Despite the prevalence of NSAID use, to our knowledge only two studies have 
directly investigated sex differences in the analgesic response of NSAIDs alone. Both 
studies were conducted by the same laboratory, and demonstrate greater analgesic 
efficacy of ibuprofen in males relative to females (Walker and Carmody, 1998; Butcher 
and Carmody, 2012). Studies of sex differences in analgesic efficacy of other commonly 
used NSAIDs have not been performed, however, robust sex differences have been 
observed in studies examining the prevalence of overall NSAID use (Dominick et al., 
2003; Fosbol et al., 2008). Indeed, disparate incidence rates of 57% female vs. 17% 
male for NSAID prescriptions for cancer pain have been reported (Shinde et al., 2015). 
Interestingly, post-marketing studies show that women are the greatest consumers of 
COX-2 selective inhibitors [approximately 85%; (Solomon et al., 2006)], suggesting that 
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there is a much greater demand from women for drugs that reduce pain and/or improve 
opioid effectiveness by decreasing inflammation.  
Both preclinical and clinical studies report that co-administration of COX-2 
inhibitors with morphine significantly potentiates pain-relief in both sexes (Deciga-
Campos et al., 2003; Pinardi et al., 2005; Reuben and Ekman, 2005; Aynehchi et al., 
2014). In studies of women following gynecological surgery, treatment with the COX-2 
selective inhibitor Rofecoxib significantly attenuates both surgical pain and opioid 
consumption (Sinatra et al., 2006), while treatment with parecoxib was associated with 
a lower incidence of post-operative headache and greater overall satisfaction compared 
with placebo (Luscombe et al., 2010). These studies are consistent with the present 
data demonstrating increased analgesic efficacy of opioids in females treated with 
immune-inhibiting drugs.  
In further support of this conclusion, preclinical studies show that several other 
non-opioid analgesics used to improve opioid efficacy in men and women are also glial 
inhibitors. For example, tri-cyclic antidepressants are commonly used to improve pain 
treatment (McQuay et al., 1996). The tri-cyclic paroxetine inhibits microglia activation 
(Liu et al., 2014), while the tri-cyclic amitriptyline not only inhibits microglia activation, 
but has been shown to directly improve morphine analgesia in male rats by reversing 
morphine-induced decreases in glutamate transporter expression, and suppression of 
pro-inflammatory cytokines (Tai et al., 2006). Perhaps the most relevant and highly 
studied opioid adjuvant, the anti-seizure medication gabapentin, is commonly used to 
improve opioid analgesia, reduce the negative side effects of opioids, and reduce opioid 
consumption (Bennett, 2011; Shinde et al., 2015). Gabapentin’s primary mechanism of 
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action is unclear, however, gabapentin is thought to modulate neuronal GABA synthesis 
and affect calcium gated ion channels on neurons (Taylor, 1997). In addition, 
gabapentin also inhibits the release of pro-inflammatory mediators (Yang et al., 2012) 
and promotes the release of anti-inflammatory mediators (Dambach et al., 2014) from 
microglia. Consistent with the studies presented in Chapter 2, Figure 2.3.5, gabapentin 
reverses sex differences in anti-nociception induced by tramadol in mice (Dai et al., 
2008). Interestingly, when co-administered with morphine, gabapentin also reduces 
M3G formation by ~33% in male rats (Papathanasiou et al., 2016).  
Overall, the literature suggests a pattern, that with the absence or inhibition of 
glial signaling, sex differences in anti-nociception are reduced or abolished. Inhibiting 
COX-2, a pro-inflammatory product of glia, improves opioid analgesia in men and 
women. Despite having vastly different effects on neurons, drugs such as gabapentin 
and amitriptyline are used clinically to improve analgesia in both sexes, likely through 
their similar actions on glial cells. The data presented in this dissertation directly test 
and support this theme, demonstrating that direct inhibition of glial TLR4 with (+)-
naloxone abolishes sex differences in morphine anti-nociception, resulting in equivalent 
analgesia in males and females. Further, MOR agonism in the absence of glial 
activation, as is the case with M6G, results in the complete reversal of sex differences in 
anti-nociception. Together, these studies outline a clear strategy for pain management: 
improvements in opioid analgesia can be made by inhibiting or preventing the activation 
of glia, and this may be especially beneficial for pain management in women. 
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 Future directions of pain treatment: Focus on the individual 
Pain treatment has not changed drastically over the past two hundred years, and 
opioids remain the most prevalent and highly prescribed analgesic drugs. Opioids 
themselves have been altered only slightly to benefit unique types of pain, changing in 
their analgesic efficacy relative to morphine; for example, less painful conditions may be 
treated with the weak analgesic, codeine, and more painful conditions may be treated 
with the more potent analgesic, fentanyl. However, well-known issues with opioid use, 
such as the high risk of tolerance and dependence in both sexes—as well as decreased 
analgesic efficacy and increased negative side-effects in women—have not been 
addressed with these ‘novel’ opioids. The use of glial inhibitors to treat pain is finally 
beginning to address unique mechanisms to improve the analgesic efficacy of opioids in 
both sexes, and more directly reduce the negative side effects of opiate use such as 
hyperalgesia, tolerance, and dependence.  
As we move forward, one thing is clear: it is important to consider sex differences 
in all pain research, both preclinical and clinical. It is not enough to include women in 
clinical studies and ignore them during data analysis. For example, although both men 
and women were included in recent clinical trials of COX-2 inhibitors, only 20% of the 28 
clinical studies on rofecoxib (Cascales Perez et al., 2003), and 14% of the clinical 
studies of etoricoxib (Chilet-Rosell et al., 2009) stratified or analyzed their data by sex. 
Currently, examination of sex differences in the efficacy of analgesics is severely (and 
disappointingly) underrepresented in both preclinical and clinical studies.   
The overall message of this dissertation is not that females should be given 
special treatment in pain research, rather, that men and women require different 
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treatment in order to achieve equal health outcomes. Furthermore, this body of work 
advocates for the study pain and immune function in both men and women because it 
uniquely effects the daily lives of so many individuals suffering from pain. Preclinical 
studies investigating pain and pain management should carefully consider biological sex 
when planning experiments, and it should go without saying that clinical studies need to 
analyze all possible aspects of their data—not just sex, but age and race as well. 
Careful investigation of sex-specific effects will not only provide a more complete 
understanding of the biological system but will facilitate new options for individualized 
treatment in both men and women. 
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Table 3. Observed Mechanisms Underlying Sex Differences in Analgesia and Hyperalgesia. 
Manipulation 
Sex / 
Species 
Drug / 
Analgesic 
Treatment 
Nociceptive 
Test 
Effect on 
Analgesia 
(relative to 
control) 
Procedural 
Comments 
Reference 
Reproductive hormones 
Adult: GDX 
Early life: 
Females+T 
or 
Males+GDX 
 
M/F; SD 
rat 
Morphine, s.c. Hotplate 
−  Adult 
Males/Females 
↓  Young Males + 
GDX 
↑  Young 
Females + T 
Indicates 
organizational but 
not activational 
effects of hormones 
(Cicero et al., 
2002) 
E2 (chronic) 
F; SD 
rat 
Morphine, 
Cumulative 
(total 3.2 
mg/kg; s.c.) 
Hotplate 
Warm 
water tail-
withdrawal 
↑  at 4h; 
↓  at 24h* and 
48h. 
*24h for tail-
withdrawal test only 
(Craft et al., 
2008) 
GDX 
M/F; 
albino 
rat 
Morphine (5 
doses 1-
40ug; i.c.v.) 
Tail-flick, 
shock 
 
−  
Males/Females 
Analgesia ↓ at 
proestrus but not 
estrus or diestrus in 
intact females 
(Kepler et al., 
1989) 
GDX 
M/F; 
albino 
rat 
Morphine (5 
doses 1-
10ug; intra-
PAG) 
Hotplate 
−   Males 
↑ Females* 
*Analgesia 
increased at high but 
not low doses 
(Krzanowska 
and Bodnar, 
1999) 
E2, P, 
E2+P4 
(chronic) 
OVX F; 
SD rat 
Morphine, 
(5mg/kg s.c.) 
Hotplate 
↓  with E2, P4, or 
E2+P4 
 
(Ratka and 
Simpkins, 1991) 
NMDA 
NMDA 
antagonism 
(Dextrometh
orphan 
[DXMP], 
ketamine, 
MK-801) 
M/F; SD 
rat 
Morphine 
(3mg/kg; s.c.) 
Tail-flick 
DXMP: 
     ↑ Males 
     ↑ Females 
Ketamine: 
     − Males 
     ↑ Females 
MK-801: 
      −  Males 
     ↑ Females 
Antagonist 
increased F 
analgesia at high 
doses only 
(Holtman et al., 
2003) 
NMDA 
antagonism 
(MK-801) 
M/F 
deer 
mice 
Morphine 
(1mg/kg; i.p.) 
Hotplate 
↓ Males 
↓ Females 
 
Complete 
attenuation in males, 
partial attenuation in 
females 
(Lipa and 
Kavaliers, 1990) 
NMDA 
antagonism 
(Mk-801) 
±GDX 
 
M/F; 
SW 
mice 
Forced swim Hotplate 
↓ Intact Males 
−  Intact Females 
↓ GDX Males 
↓ GDX Females 
 
(Mogil et al., 
1993) 
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NMDA 
antagonism 
(Dextrometh
orphan 
[DXMP), 
Dextrorphan 
[DXTP], 
MK-801, 
LY235959, 
L-701324, 
Ro25-6981) 
M/F; 
CD1 
mice 
Morphine (15, 
25, 35 and 45 
mg/kg; i.p.) 
Tail-flick 
DXMP: 
     ↑/↓ Males 
     −/−  Females 
DXTP:  
     ↑/− Males 
     −/− Females 
MK-801: 
     ↑/− Males 
     −/− Females 
LY235959: 
     ↑/↑ Males 
     ↑/↑Females 
L-70132: 
     ↑/↑ Males 
     ↑/↑Females 
Ro25-6981: 
     −/↓ Males 
     −/↓Females 
*Results show 
effects of 
antagonists on 
LOW (15, 25mg/kg) / 
HIGH (35, 45 mg/kg) 
doses of morphine 
analgesia 
(Nemmani et al., 
2004) 
NMDA 
antagonism 
(MK-801); 
± 
Progesteron
e 
M/ 
OVXF
; CD1 
mice 
Morphine (40 
mg/kg)* 
Tail-
withdrawal 
↑ Intact Males 
−  Intact Males + 
P 
−  Intact Females  
↑ OVX Females 
− OVX Females + 
P 
*Measures morphine 
hyperalgesia. Here, 
increased analgesia 
reflects decreased 
hyperalgesia 
(Waxman et al., 
2010) 
MOR 
MOR 
antagonism 
M/F; 
SD 
rat 
Morphine (0.3, 
1.0, 3.0, or 
10ug); s.c. 
Tail 
withdrawal 
↓  Males 
↓ Females* 
*Antagonist more 
potent in females 
(Bernal et al., 
2007) 
MOR 
antagonism 
M/F; 
SD 
rat 
Fentanyl, 
morphine, 
buprenorphine 
Hotplate 
↓  Males 
↓ Females* 
*Antagonist more 
potent in females  
(Craft et al., 
2001) 
MOR lesions  
± 
inflammatory 
CFA 
M/F; 
SD 
rat 
Morphine 
Cumulative (up 
to 18mg/kg); 
s.c. 
Hotplate 
PWL 
↓ Males 
−  Females 
 
(Loyd et al., 
2008a) 
MOR 
antagonism 
M/F; 
SD 
rat 
Morphine, 
(cumulative up 
to 10mg/kg);s.c. 
Wail 
withdrawal 
↓  Males 
↓ Females* 
*Antagonist more 
potent in females 
(Peckham et al., 
2005) 
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Table 4. Mechanisms Attributed to Sex Differences in Morphine Analgesia Share an Inverse Relation with 
Inflammatory Markers. 
Manipulation 
Model / 
Tissue  
Immune 
challenge 
Effect on Pro-
Inflammatory 
Markers 
Procedural 
comments 
Reference 
Reproductive hormones 
Note: Given known discrepancies between in vitro and in vivo application of steroid hormones, studies included in 
this table are limited to in vivo application of hormones only.  
E2  
OVX 
Female 
C57BL/6J 
mice 
LPS ex vivo ↑  
E2 for 4 weeks 
before testing 
(Calippe et al., 
2008) 
E2 
Intact M/  
OVX F; SD 
rat 
LPS ex vivo 
−   Male 
↑ Female 
E2 for 12 days 
before testing 
(Loram et al., 2012) 
E2, P4, E2+P4 
OVX 
Female 
C57BL/6 
mice 
LPS in vivo 
− P4 
↑ E2 
↑ E2+P4 
E2, P4 for 5 weeks 
before testing 
(Rettew et al., 
2009) 
OVX 
Female 
CD1 and 
C57BL/6J 
mice 
LPS in vivo 
↓ 24h post-LPS 
−   3d, 7d post-
LPS 
 (Soucy et al., 2005) 
NMDA 
NMDA 
antagonism 
(DXMP) 
BV2 
microglia 
cell line 
LPS in vitro ↓  
(Cheng et al., 
2015) 
NMDA 
antagonism 
(MK-801) 
Sex not 
specified; 
1d old 
Wistar rat  
Hypoxia in 
vivo 
↓  
(Murugan et al., 
2011) 
NMDA 
antagonism 
(MK-801) 
M/F; rat None 
−   Male 
↑ Female 
 
(Nieto-Sampedro et 
al., 1991) 
NMDA 
antagonism 
(MK-801, 
DXMP) 
BV2 
microglia 
cell line 
LPS in vitro ↓  
(Thomas and Kuhn, 
2005) 
MOR 
MOR antagonist  
[(-)-Naloxone] 
Male; SD 
rat 
 
Chronic 
constriction 
injury in vivo 
↓ *CNS inflammation 
(Hutchinson et al., 
2008a) 
MOR-KO 
Sex not 
specified; 
B6 
background 
Restraint 
stress + 
allergen 
−    
*Suggests in the 
absence of MOR, 
there is no 
challenge-induced 
increase in 
inflammation 
(Okuyama et al., 
2010) 
MOR agonism 
(morphine) 
Male; SD 
rat 
L5 spinal 
nerve injury 
↑ 
*CNS inflammation; 
Increases in 
immune activation 
linked with 
decreases in 
analgesia and 
increases in 
morphine tolerance 
(Raghavendra et 
al., 2002) 
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